###begin article-title 0
###xml 93 98 <span type="species:ncbi:9606">human</span>
Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: Independent modulation of TPalpha signaling by prostacyclin and nitric oxide
###end article-title 0
###begin p 1
This document may be redistributed and reused, subject to .
###end p 1
###begin title 2
Abstract
###end title 2
###begin p 3
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 89 90 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 390 392 366 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1411 1412 1339 1340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 639 644 <span type="species:ncbi:9606">human</span>
In humans, thromboxane (TX) A2 signals through the TPalpha and TPbeta isoforms of the TXA2 receptor that exhibit common and distinct roles. For example, Gq/phospholipase (PL)Cbeta signaling by TPalpha is directly inhibited by the vasodilators prostacyclin and nitric oxide (NO) whereas that signaling by TPbeta is unaffected. Herein, we investigated whether TPalpha and/or TPbeta regulate G12/Rho activation and whether that signaling might be differentially regulated by prostacyclin and/or NO. Both TPalpha and TPbeta independently regulated RhoA activation and signaling in clonal cells over-expressing TPalpha or TPbeta and in primary human aortic smooth muscle cells (1degrees AoSMCs). While RhoA-signaling by TPalpha was directly impaired by prostacyclin and NO through protein kinase (PK)A- and PKG-dependent phosphorylation, respectively, signaling by TPbeta was not directly affected by either agent. Collectively, while TPalpha and TPbeta contribute to RhoA activation, our findings support the hypothesis that TPalpha is involved in the dynamic regulation of haemostasis and vascular tone, such as in response to prostacyclin and NO. Conversely, the role of TPbeta in such processes remains unsolved. Data herein provide essential new insights into the physiologic roles of TPalpha and TPbeta and, through studies in AoSMCs, reveal an additional mode of regulation of VSM contractile responses by TXA2.
###end p 3
###begin title 4
Abbreviations
###end title 4
###begin title 5
Keywords
###end title 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 405 408 405 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1" ref-type="bibr">[1]</xref>
###xml 532 533 532 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 570 571 570 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 578 579 578 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 654 657 654 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1" ref-type="bibr">[1]</xref>
###xml 683 684 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 825 827 822 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 894 896 891 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 913 918 910 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2" ref-type="bibr">[1,2]</xref>
###xml 947 949 944 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1005 1007 1002 1004 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1028 1031 1025 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1" ref-type="bibr">[1]</xref>
###xml 1034 1036 1031 1033 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1065 1067 1058 1060 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1405 1410 1391 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib3 bib4 bib5" ref-type="bibr">[3&#8211;5]</xref>
###xml 1559 1561 1545 1547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1658 1665 1644 1651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib4 bib5" ref-type="bibr">[2,4,5]</xref>
###xml 1843 1846 1829 1832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4" ref-type="bibr">[4]</xref>
###xml 1880 1882 1866 1868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2191 2198 2177 2184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2 bib6" ref-type="bibr">[1,2,6]</xref>
The phosphorylation status of myosin light chain (MLC) of the actomyosin complex plays a central role in regulating the various types of cytoskeletal reorganizations that widely occur within the vasculature including in platelet shape change and aggregation, tonic- or agonist-induced contraction and relaxation of smooth muscle cells (SMCs), cell migration, cell proliferation and stress fibre formation [1]. Many of the physiologic regulators of platelets and vascular smooth muscle (VSM) contraction, including thromboxane (TX) A2, thrombin, ADP, prostaglandin (PG) I2 or PGD2, act through specific G protein coupled receptor (GPCR) -effector systems [1]. While agents such as TXA2 and thrombin that promote platelet activation or SMC contraction induce Gq-dependent phospholipase (PL)Cbeta activation to evoke calcium (Ca2+) -dependent activation of myosin light chain kinase (MLCK) and MLC20 phosphorylation [1,2], they may also engage the Ca2+-independent pathway involving receptor co-coupling to G12 and RhoA signalling [1]. G12 members, particularly Galpha13, activate RGS (regulators of G protein signaling)-box containing members of the Rho guanine nucleotide exchange factor (RhoGEF) family, such as p115 RhoGEF, PDZ RhoGEF or LARG, to activate RhoA and its key effector in this system Rho kinase 1 (also known as p164 ROKalpha/ROCK2) and 2 (p160 ROKbeta/ROCK1), herein termed Rho kinase/ROCK [3-5]. Rho kinases, in turn, phosphorylate, and inactivate, myosin phosphatase, MLC itself and the myosin phosphatase inhibitor CPI-17 resulting in the Ca2+-independent increase in overall levels of phosphorylated MLC through a Rho/Rho kinase-mechanism [2,4,5]. Other targets of Rho kinase include its phosphorylation-dependent activation of LIM kinases which, in turn, phosphorylate and inactivate the actin depolymerizing agent cofilin [4]. The central importance of the Ca2+-independent mechanism of contraction within the vasculature has been highlighted through findings that disorders of the Rho/Rho kinase pathway are major underlying causes of hypertension, vascular spasm and atherosclerosis making Rho kinase an important therapeutic target in the treatment of these diseases [1,2,6].
###end p 7
###begin p 8
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 353 356 353 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
###xml 409 410 406 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 444 446 441 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 462 467 459 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12/13</sub>
###xml 484 486 481 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 529 534 526 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib8" ref-type="bibr">[1,8]</xref>
###xml 570 572 563 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 663 664 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 704 706 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 779 782 772 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9" ref-type="bibr">[9]</xref>
###xml 802 804 795 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 829 831 819 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 877 878 867 868 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 980 987 970 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10 bib11 bib12" ref-type="bibr">[10&#8211;12]</xref>
###xml 1045 1046 1035 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1088 1089 1078 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1241 1248 1224 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13 bib14 bib15" ref-type="bibr">[13&#8211;15]</xref>
###xml 1542 1549 1511 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16 bib17 bib18 bib19 bib20 bib21" ref-type="bibr">[16&#8211;21]</xref>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
###xml 911 917 <span type="species:ncbi:9913">bovine</span>
###xml 1009 1015 <span type="species:ncbi:9606">humans</span>
The prostanoid TXA2 plays an essential role within the vasculature inducing a diversity of cellular responses including platelet shape change, secretion and aggregation, VSMC contraction and migration and is widely implicated in a number of cardiovascular disorders including thrombosis, hypertension, vessel remodelling and atherosclerotic progression [7]. As a predominantly Gq/PLCbeta-coupled GPCR, the TXA2 receptor or TP can induce both Ca2+-dependent and G12/13-mediated RhoA/Ca2+ independent responses platelets and VSMCs [1,8]. For example, platelets from Galpha13-deficient mice do not undergo RhoA-dependent shape change in response to low levels of TXA2 but retain the ability to undergo Gq/Ca2+-dependent shape change and aggregation at higher agonist concentrations [9]. Similarly, both Ca2+-dependent/PLCbeta and Ca2+-independent/RhoA mechanisms contribute to TXA2-induced contraction in isolated bovine aortic (Ao) SMCs and in VSM tissue from various other species [10-12]. Notably however, in humans, but not in non-primates, TXA2 actually signals through two distinct TXA2 receptor isoforms termed TPalpha and TPbeta that arise through alternative splicing and differ exclusively in their carboxyl-terminal (C tail) domains [13-15]. Whilst it is currently unknown whether TPalpha or TPbeta independently or indeed differentially modulate RhoA activation and downstream signaling, there is substantial evidence that the TPalpha and TPbeta isoforms can differentially regulate other cellular effectors raising that possibility [16-21].
###end p 8
###begin p 9
###xml 81 85 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib22" ref-type="bibr">[22]</xref>
###xml 230 234 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23" ref-type="bibr">[23]</xref>
###xml 337 341 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24" ref-type="bibr">[24]</xref>
###xml 448 455 423 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25 bib26" ref-type="bibr">[25,26]</xref>
###xml 561 562 536 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 610 611 585 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 832 835 793 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 868 875 829 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21 bib27" ref-type="bibr">[21,27]</xref>
###xml 1112 1116 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
###xml 1686 1687 1618 1619 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1924 1926 1842 1844 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 2362 2363 2267 2268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 432 437 <span type="species:ncbi:9606">human</span>
###xml 1756 1761 <span type="species:ncbi:9606">human</span>
###xml 2215 2220 <span type="species:ncbi:9606">human</span>
While both TPalpha and TPbeta are predominantly coupled to Gq/PLCbeta activation [22], they can independently regulate other secondary effector systems including opposite regulation of adenylyl cyclase via Gs and Gi, respectively [23]. Additionally, TPalpha, but not TPbeta, couples to PLCdelta activation via Gh/tissue transglutaminase [24]. Whereas both TPs are expressed in VSMCs, TPalpha is the predominant isoform expressed in human platelets [25,26]. Consistent with this, in studies investigating intermolecular cross talk between the pro-aggregatory TXA2 and the inhibitory prostanoid prostacyclin (PGI2), it was established that Gq/PLCbeta coupling and signaling by TPalpha, but not TPbeta, undergoes prostacyclin- induced desensitization mediated through direct cAMP-protein kinase (PK) A phosphorylation of TPalpha at Ser329 within its unique C-tail domain [21,27]. Moreover, Gq/PLCbeta signaling by TPalpha, but not TPbeta, is also desensitized by the platelet antagonist /vasodilator nitric oxide (NO), involving direct NO/cGMP-dependent PKG phosphorylation of TPalpha also within its unique C-tail [20] The implication from these studies is that TPalpha plays a critical role in vascular haemostasis acting as the major TP target for regulation/inhibition by prostacyclin and NO, such as within the anucleate platelet that predominantly expresses TPalpha. However, the impact of such direct inhibitory effects of prostacyclin and NO mediated by PKA and PKG, respectively, on signaling by TPalpha and TPbeta through other effector systems, such as through RhoA, is currently unknown but, clearly, any differential regulatory effects by either prostacyclin or NO on such TXA2 signaling may have direct clinical implications, for example within human VSMCs that express both TPalpha and TPbeta isoforms. Hence, the aim of the current study was to investigate whether TPalpha and/or TPbeta independently regulate G12/Rho activation and signaling and to establish whether that signaling is differentially regulated by the inhibitory prostacyclin/cAMP/PKA and NO/cGMP/PKG systems. These studies provide essential new insights into the physiologic roles of TPalpha and TPbeta and, through studies in primary human aortic smooth muscle cells (1degrees AoSMCs), reveal an additional mode of regulation of VSM contractile responses by the potent autocoid TXA2.
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
Materials
###end title 11
###begin p 12
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 288 294 288 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser188</sup>
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 320 325 316 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12/13</sub>
###xml 344 348 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 391 395 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 434 438 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 478 482 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 594 598 586 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 627 631 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 653 657 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 682 686 674 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser3</sup>
###xml 784 794 774 784 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">495/518&#160;nm</sub>
###xml 819 823 809 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1093 1104 1075 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209l,D277N</sup>
###xml 1117 1119 1095 1097 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1119 1124 1097 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G228A</sup>
###xml 1140 1142 1114 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1142 1147 1116 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G225A</sup>
###xml 149 160 <span type="species:ncbi:3704">horseradish</span>
###xml 386 390 <span type="species:ncbi:9925">goat</span>
###xml 396 401 <span type="species:ncbi:10090">mouse</span>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
###xml 439 443 <span type="species:ncbi:9925">goat</span>
###xml 473 477 <span type="species:ncbi:9925">goat</span>
###xml 483 489 <span type="species:ncbi:9986">rabbit</span>
###xml 589 593 <span type="species:ncbi:9925">goat</span>
###xml 599 605 <span type="species:ncbi:9986">rabbit</span>
U46619, SQ29,548, BW245C, FK409, FURA2/AM were purchased from Cayman Chemical Company; SIN-1 and Y-27632 from Calbiochem; 3F10 anti-HA, 3F10 anti-HA-horseradish peroxidase (HRP)-conjugated antibody and chemiluminescence detection kit from Roche; anti-RhoA 26C4 (Sc-418), anti-phospho-RhoASer188 (Sc-32954-R), anti-Galpha12/13 H-300 (Sc-28588), anti-Galphaq C15 (SC-392), HRP-conjugated goat anti-mouse (Sc-2005), HRP-conjugated mouse anti-goat (Sc-2354) and HRP-conjugated goat anti-rabbit (Sc-2004) antibodies from Santa Cruz; Glutathione-Sepharose 4B (GE Healthcare) and FITC conjugated goat anti-rabbit antibody from Sigma; anti-cofilin (# 3312) and anti-phospho-cofilin (phosphoSer3, # 3311) were from Cell Signaling; Alexa Fluor(R) 488 phalloidin (A12379; Excitation / Emission A495/518 nm) from Molecular Probes; anti-HDJ2 antibody from Neomarkers; Opti-MEM(R) and Oligofectamine(R) were from Invitrogen. All oligonucleotides were synthesised by Genosys Biotechnologies; small interfering (si) RNAs by Qiagen. Cicaprost was a gift from Schering AG (Berlin, Germany). pcDNA3.1(+):hGalphaqQ209l,D277N, pCis:Galpha12G228A and pCis:Galpha13G225A were from the UMR cDNA Resource Center (Galphaq) or from Dr S. Offermanns, University of Heidelberg, Germany.
###end p 12
###begin title 13
Cell culture and transfections
###end title 13
###begin p 14
###xml 152 157 141 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 169 174 154 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 190 199 171 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 294 299 264 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 307 312 273 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 324 333 286 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 379 386 341 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 475 476 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 660 664 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 96 102 <span type="species:ncbi:9913">bovine</span>
Human embryonic kidney (HEK) 293 cells were grown in minimal essential medium (MEM), 10% foetal bovine serum (FBS). HEK.TPalpha, HEK.TPbeta, HEK.TPalphaS329A HEK.TPalphaS331A and HEK.TPalphaS329,331A cell lines stably over-expressing hemagglutinin (HA) -tagged forms of TPalpha, TPbeta, TPalphaS329A,TPalphaS331A and TPalphaS329,331A respectively, have been previously described [20,21]. For transfections, HEK 293 cell lines were routinely plated 48 h previously at ~ 2 x 106 cells/10 cm dish in 8 ml media and co-transfected with 10 mug of pADVA and 25 mug of pCMV-based mammalian expression vector using the calcium phosphate/DNA co-precipitation procedure [20].
###end p 14
###begin p 15
###xml 19 24 <span type="species:ncbi:9606">human</span>
Primary (1degrees) human aortic smooth muscle cells (1degrees h.AoSMCs) were purchased from Cascade Biologics (C-007-5C) and routinely grown in Smooth Muscle Cell Growth Medium 2 (Promocell GMBH, C-22062) supplemented with 0.5 ng/ml epidermal growth factor, 2 ng/ml basic Fibroblast growth factor, 5 mug/ml insulin, 5% FBS.
###end p 15
###begin title 16
Calcium measurements
###end title 16
###begin p 17
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 209 213 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
###xml 356 382 341 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">Supplemental Figs. 1 and 2</xref>
###xml 479 481 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 501 503 482 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 504 505 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 504 505 485 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
Measurements of intracellular calcium ([Ca2+]i) mobilization were carried out in FURA2/AM preloaded HEK 293 cell lines transiently co-transfected with pCMV:Galphaq and pADVA some 48 h previously, as described [20]. Cells were stimulated with 1 microM U46619, 1 microM Cicaprost, 1 muM BW245C, 5 muM SIN-1 or 10 muM FK409, unless otherwise specified. Data (Supplemental Figs. 1 and 2) are representative of 3-4 independent experiments and calculated as changes in intracellular Ca2+ mobilized (Delta[Ca2+]i (nM)) as a function of time (seconds, s) following ligand stimulation.
###end p 17
###begin title 18
Determination of RhoA activation and cofilin phosphorylation
###end title 18
###begin p 19
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr">[28]</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr">[28]</xref>
###xml 357 362 346 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 374 379 359 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 392 401 373 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 800 801 768 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1152 1154 1115 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1157 1159 1120 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Activated cellular Rho was determined by interaction with a purified glutathione-S-transferase: rhotekin Rho-binding domain (GST-RBD) fusion protein immobilized on Glutathione-Sepharose 4B resin [28]. Preparation of the GST-RBD protein was carried out as previously reported [28]. For the 'Rho-pulldown assay', in brief, HEK.TPalpha, HEK.TPbeta, HEK.TPalphaS329A HEK.TPalphaS331A, HEK.TPalphaS329,331A or 1degrees h.AoSMCs cells were plated some 48 h previously in complete growth medium onto 10-cm dishes to achieve ~ 70% confluency; cells were then serum starved for 5 h or 20 h (1degrees h.AoSMCs cells) in growth media containing 0.1% FBS before stimulation for 0-30 min with 0-10 muM U46619, as indicated in specific figure legends. To assess the effect of prostacyclin, nitric oxide (NO) or PGD2 on TP-mediated Rho signaling, cells were pre-incubated for 10 min with either 0.01-10 muM Cicaprost; 0.05-50 muM SIN-1; 10 muM FK409 or 1 muM BW245C before stimulation with U46619 (typically 0.1 muM for 10 min). As controls, cells were incubated with an equivalent volume of the drug vehicle, agonist or inhibitor in 0.01% ethanol in HBS (modified Ca2+/Mg2+-free Hank's buffered salt solution) for equivalent incubation times.
###end p 19
###begin p 20
###xml 134 135 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 184 188 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr">[29]</xref>
###xml 344 348 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr">[28]</xref>
###xml 471 475 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 551 555 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr">[21]</xref>
###xml 797 801 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1055 1059 1049 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1067 1071 1061 1065 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser3</sup>
###xml 1160 1164 1154 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
Thereafter, cells were lysed in 800 mul Lysis Buffer (125 mM HEPES, pH 7.5, 750 mM NaCl, 5 mM EDTA, 5% NP-40, 10% glycerol, 50 mM MgCl2, and 10 mug/ml each of leupeptin and aprotinin; [29]) and aliquots (600 mul) were subjected to pulldown using Glutathione-Sepharose 4B beads preloaded with 30 mug GST-RBD, essentially as previously described [28]. Following washing, precipitated GTP-bound RhoA was subjected to SDS-PAGE on 12.5% acrylamide gels and immunoblotted with anti-RhoA monoclonal antibody (Sc-418), followed by chemiluminescence detection [21]. In parallel, to confirm equivalent RhoA protein expression in the cell lysates and uniform protein loading, aliquots of whole cell lysates (typically 10 mul, corresponding to 1.25% of total cell lysate) were directly immunoblotted with the anti-RhoA antibody and/or with the anti-HDJ2 antibody. Similarly, to assess U46619-mediated cofilin phosphorylation and activation, aliquots of whole cells lysates (typically 10 mul, corresponding to 1.25% of total cell lysate) were first immunoblotted with anti-phosphoSer3 cofilin antibody; thereafter, phospho-cofilin blots were stripped and rescreened versus anti-cofilin antibody to normalise for total cofilin protein expression and/or with the anti-HDJ2 antibody to confirm uniform protein loading in each of the assays. All images of RhoA expression/pulldown or cofilin phosphorylation and/or expression were captured using Adobe Photoshop (V6), where band width and intensity was quantified and represented as fold increases relative to basal levels. To account for biological variations in basal activation levels, experiments were normalised to within a comparable range based on measurements from more then 20 individual experiments for each cell type.
###end p 20
###begin title 21
F-actin staining
###end title 21
###begin p 22
HEK 293 cell lines or 1degrees h.AoSMCs, grown on coverslips for 3 days to achieve approximately 50% confluency, were serum-starved for 2 h in growth media containing 0.1% FBS, prior to stimulation with U46619 (0-1 muM; typically 10 nM U46619). To assess the role of prostacyclin or NO, cells were pre-incubated for 10 min with either 0.01-10 muM Cicaprost or 0.05-50 muM SIN-1 before stimulation with U46619 (typically 10 nM for 10 min). F-actin polymerization was stained by the addition of Alexa Fluor(R) 488 phalloidin essentially as described by the supplier (Molecular Probes) and slides were imaged using an Axioplan 2 Imaging Universal Microscope.
###end p 22
###begin title 23
Disruption of TPa and TPbeta expression by small interfering (si) RNA
###end title 23
###begin p 24
###xml 7 19 7 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interference</italic>
###xml 7 19 7 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>interference</italic></sub>
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 163 164 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 386 393 360 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 571 577 537 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 1145 1155 1095 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vice versa</italic>
For RNAinterference (RNAi) experiments, HEK 293 cell lines (HEK.TPalpha, HEK. TPbeta and, as controls, HEK293 cells) or 1degrees h.AoSMCs were plated at ~ 2.5 x 105 cells /35-mm plate and were allowed to attach for 24 h, achieving ~ 30 % confluency. Thereafter, cells were washed twice with serum-free Opti-MEM(R) and transfected for 4 h at 37 degreesC with 0.2 muM TPalpha siRNA (siRNATPalpha; a 50:50 mixture of two individual 19 bp siRNAs duplexes corresponding to nucleotides 2003-2021 and 2380-2398 of GenBank accession , respectively) or 0.2 muM TPbeta siRNA (siRNATPbeta; a 50:50 mixture of two individual 19 bp siRNAs duplexes corresponding to nucleotides 1966-1974 + 2634-2644 and 1970-1974 + 2634-2647 of GenBank accession , respectively) or 0.2 muM Lamin A/C siRNA (5'-CUGGACUUCCAGAAGAACAtt) using Oligofectamine(R) (3 mul/well) in Opti-MEM(R) (1 ml /well). Thereafter, 1 ml pre-warmed complete media supplemented with 30% FCS was added per well and cells were harvested following incubation at 0, 24, 48, and 72 h. As additional controls, HEK.TPalpha cells were treated according to the latter conditions but using TPbeta siRNAs and vice versa.
###end p 24
###begin p 25
###xml 270 274 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 343 347 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 597 601 576 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 625 629 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 659 663 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">[30]</xref>
###xml 590 596 <span type="species:ncbi:9986">rabbit</span>
###xml 890 894 <span type="species:ncbi:9925">goat</span>
###xml 900 906 <span type="species:ncbi:9986">rabbit</span>
To confirm the efficacy of the siRNAs to disrupt TPalpha or TPbeta expression, HEK 293 cell lines were harvested and subject to SDS-PAGE (25-50 mug/lane on 12.5% gels) followed by electroblotting onto PVDF membranes (Roche). Membranes were initially screened versus the anti-HA (3F10) antibody and, following stripping, were rescreened versus anti-HDJ antibody to confirm uniform protein loading. Similarly, 1degrees h.AoSMCs were screened, under permabilising conditions, by indirect immunofluorescence microscopy for TPalpha and TPbeta expression using affinity purified isoform specific rabbit anti-TPalpha (3 mug/ml) and anti-TPbeta (3 mug/ml) antibodies [30] incorporating tyramide signal amplification (TSA system; Invitrogen), used as per the manufacturer's instructions. In brief, following incubation with the primary antibodies, 1degrees h.AoSMCs were incubated with biotinylated goat anti-rabbit (1 in 500 dilution), followed by streptavidin HRP (1 in 2000). Signal amplification was facilitated by incubating the HRP labeled cells with biotinylated tyramide for 10 min at room temperature. Thereafter, 1degrees h.AoSMCs were incubated with streptavidin FITC (1 in 1000 dilution) and counterstained with propidium iodide (20 mug/ml), prior to mounting and imaging using a Zeiss fluorescence microscope coupled with AxioVision Software (V 4.4).
###end p 25
###begin p 26
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 202 203 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Thereafter, having optimised the conditions for effective RNAi disruption of TPalpha or TPbeta expression in respective HEK 293 lines and in 1degrees h.AoSMCs, experiments was scaled up 8.2-fold (2 x 106 cells on 10-cm dishes) and functional disruption was assessed through Rho pulldown assays or cofilin phosphorylation, as previously outlined herein.
###end p 26
###begin title 27
Data analyses
###end title 27
###begin p 28
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</italic>
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 89 92 89 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 168 169 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 213 215 213 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
Radioligand binding data was analyzed using GraphPad Prism V3.0 to determine the Kd and Bmax values. Statistical analyses were carried out using the unpaired Student's t test using the Statworks Analysis Package. p-values of less than or equal to 0.05 were considered to indicate a statistically significant difference. Throughout the figures, ⁎ < 0.05, ⁎⁎< 0.01, ⁎⁎⁎< 0.001.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 71 73 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
TPalpha and TPbeta isoforms independently regulate the Gq/PLCbeta and G12/Rho signaling systems
###end title 30
###begin p 31
###xml 124 125 114 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 447 448 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 657 659 609 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 660 661 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 660 661 612 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 153 158 <span type="species:ncbi:9606">human</span>
Whilst a range of studies have investigated Gq/PLCbeta-mediated signaling by both the TPalpha and TPbeta isoforms of the TXA2 receptor (TP) expressed in human tissues, to our knowledge, no such study has investigated the propensities or relative abilities of the individual TPalpha or TPbeta isoforms to activate and/or regulate Rho-mediated signaling. Hence, herein we investigated TPalpha and TPbeta-mediated Rho signaling in response to the TXA2 mimetic U46619 in clonal HEK 293 cell lines that stably over-express either TPalpha (HEK.TPalpha cells) or TPbeta (HEK.TPbeta cells). Throughout these studies, TPalpha/TPbeta-mediated Gq/PLCbeta-dependent [Ca2+]i mobilization was monitored as a comparative reference.
###end p 31
###begin p 32
###xml 33 40 33 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 191 193 177 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 194 195 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 194 195 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 284 290 269 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 292 309 277 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">Supplemental Data</xref>
###xml 594 600 565 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 862 868 826 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 945 947 909 911 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 955 957 915 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 964 966 920 922 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1045 1052 1001 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31 bib32 bib33" ref-type="bibr">[31&#8211;33]</xref>
###xml 1114 1116 1066 1068 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1124 1126 1072 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1126 1131 1074 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G228A</sup>
###xml 1161 1173 1101 1113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209&#160;l,D277N</sup>
###xml 1253 1254 1189 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1268 1269 1204 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1305 1306 1238 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1320 1321 1253 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1345 1351 1278 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
Consistent with previous reports [20,21], both TPalpha and TPbeta expressed in HEK.TPalpha cells and HEK.TPbeta cells, respectively, showed similar concentration-dependent mobilization of [Ca2+]i in response to U46619 stimulation, with maximal responses generated using 1 muM U46619 (Fig. 1; Supplemental Data). Moreover, both TPalpha and TPbeta also mediated rapid RhoA activation in HEK.TPalpha and HEK.TPbeta cells in response to U46619 stimulation while no such activation was observed in the vehicle-treated cells or in the control non-transfected HEK 293 cells in the presence of U46619 (Fig. 1A). From concentration-response studies, 10-100 nM U46619 was required for maximal RhoA activation by both TPalpha and TPbeta while time-course assays confirmed that this was rapid, occurring within 2 min, and sustained for at least 30 min for both TP isoforms (Fig. 1A and B). RhoA activation through GPCRs predominantly occurs by coupling to G12 (Galpha12/Galpha13) members but may also occur through Gq coupling, in certain settings at least [31-33]. Herein, over-expression of dominant negative forms of Galpha12 (Galpha12G228A), but not of Galphaq (GalphaqQ209 l,D277N), significantly impaired U46619-mediated RhoA activation through both TPalpha (p = 0.0011 and p = 0.8011 respectively) and TPbeta (p = 0.0043 and p = 0.9235 respectively; Fig. 1C).
###end p 32
###begin p 33
###xml 255 259 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 309 310 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 310 314 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">[34]</xref>
###xml 698 704 683 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 904 910 881 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1063 1069 1040 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1206 1208 1179 1181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1216 1218 1185 1187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1218 1223 1187 1192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G228A</sup>
###xml 1278 1289 1239 1250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209l,D277N</sup>
###xml 1318 1324 1279 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
To extend these studies, we also examined U46619-mediated stress fibre formation in HEK.TPalpha and HEK.TPbeta cells by monitoring F-actin polymerization and Rho-dependent phosphorylation, and inactivation, of the actin depolymerizing agent cofilin using anti-phospho-cofilin antibodies directed to phosphoSer3[34]. Throughout the latter, assays were normalised for total cofilin expression as presented in the lower panels in each of the figures. Whilst the control HEK 293 cells failed to show any changes in stress-fibre formation in response to U46619 (1 nM-10 muM), both TPalpha and TPbeta induced rapid and profound F-actin polymerization with optimal responses occurring using 10 nM U46619 (Fig. 2A). Moreover, U46619 induced rapid and concentration-dependent cofilin phosphorylation in both HEK.TPalpha and HEK.TPbeta cells with optimal responses occurring with 1 muM U46619 by both TP isoforms (Fig. 2B) while there was no cofilin phosphorylation in either cell line in response to the drug vehicle or in HEK 293 cells in response to U46619 stimulation (Fig. 2B). Furthermore, this U46619-mediated phosphorylation of cofilin was inhibited by over-expression of the dominant negative form of Galpha12 (Galpha12G228A), while the dominant negative form of Galphaq (GalphaqQ209l,D277N) had no significant effect (Fig. 2C). The Rho kinase inhibitor Y27632 (10 muM) effectively abolished U46619-induced cofilin phosphorylation by both TPalpha and TPbeta (data not shown).
###end p 33
###begin p 34
###xml 141 143 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 151 152 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 205 207 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
Collectively, these data confirm that both TPalpha and TPbeta can independently couple to both Gq-dependent PLCbeta activation to mobilize Ca2+ from IP3-operated intracellular stores, for example, and to G12-dependent RhoA activation and effector coupling leading to cofilin phosphorylation and inactivation and to F-actin polymerization.
###end p 34
###begin title 35
The effect of prostacyclin/cAMP and NO/cGMP on TPalpha- and TPbeta-mediated PLCbeta- and RhoA-signaling
###end title 35
###begin p 36
###xml 111 115 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib22" ref-type="bibr">[22]</xref>
###xml 264 268 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr">[21]</xref>
###xml 290 291 283 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 291 295 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">[27]</xref>
###xml 313 317 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
###xml 463 470 446 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 608 609 591 592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 676 683 659 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35 bib36" ref-type="bibr">[35,36]</xref>
Amongst the many functional differences identified thus far between the individual TPalpha and TPbeta isoforms [22], one of the most significant relates to the differential heterologous desensitization of their signaling by the vasodilatory autocoids prostacyclin [21], prostaglandin (PG) D2[27] and nitric oxide [20]. Hence, in view of those differential sensitivities of Gq/PLCbeta-mediated signaling by TPalpha and TPbeta to both prostacyclin/cAMP and NO/cGMP [20,21], coupled to the well documented inhibitory actions of cAMP and cGMP on Rho-mediated signaling in response to various agents including TXA2 and thrombin, such as within platelets and vascular smooth muscle [35,36], we next investigated the effects of prostacyclin and NO on RhoA-mediated signaling by the individual TPalpha and TPbeta isoforms.
###end p 36
###begin p 37
###xml 120 122 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 123 124 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 123 124 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 246 253 237 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 342 344 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 345 346 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 345 346 336 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 413 419 397 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 421 438 405 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">Supplemental Data</xref>
###xml 500 506 484 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 705 711 674 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 814 820 779 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1018 1024 975 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1248 1250 1196 1198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1267 1269 1215 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1493 1499 1434 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 1690 1696 1624 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 1769 1770 1703 1704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1883 1889 1817 1823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1990 1996 1917 1923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
Initially the effect of the prostacyclin analogue Cicaprost (1 muM) or the NO-donor SIN-1 (5 muM) on U46619-mediated [Ca2+]i mobilization and RhoA activation and signaling by TPalpha and TPbeta was examined. Consistent with our previous findings [20,21], pre-incubation with either Cicaprost or SIN-1 significantly impaired U46619-induced [Ca2+]i mobilization by TPalpha but had no effect on signaling by TPbeta (Fig. 1; Supplemental Data). While Cicaprost did not induce substantial RhoA activation per se in HEK.TPalpha, HEK.TPbeta or HEK 293 cells (data not shown), it significantly impaired U46619-induced RhoA activation by TPalpha expressed in HEK.TPalpha cells in a concentration-dependent manner (Fig. 3A). On the other hand, Cicaprost had no effect on RhoA activation by TPbeta, even at 10 muM Cicaprost (Fig. 3A). Similarly, SIN-1 also significantly impaired U46619-mediated RhoA activation by TPalpha in a concentration-dependent manner but had no effect on RhoA activation by TPbeta, even at 50 muM SIN-1 (Fig. 3B). While Cicaprost (1-10 muM) and SIN-1 (5-50 muM) each significantly impaired U46619-induced F-actin polymerization by both TPalpha and TPbeta, consistent with the inhibitory effects of cAMP/PKA and cGMP/PKG on both the Ca2+-dependent and Ca2+-independent paths, it was apparent that at lower concentrations both Cicaprost (100 nM) and SIN-1 (500 nM) impaired F-actin polymerization in HEK.TPalpha cells but neither agent affected such responses in HEK.TPbeta cells (Fig. 4A). Moreover, U46619-induced cofilin phosphorylation by TPalpha was also significantly impaired by either Cicaprost or SIN-1, while neither agent affected such responses in HEK.TPbeta cells (Fig. 4B), regardless of concentration. Consistent with the latter data, the PGD2 analogue BW245C and the alternative NO donor FK409 also significantly impaired U46619-mediated RhoA activation (Fig. 3C) and cofilin phosphorylation (data not shown) by TPalpha but had no effect on signaling by TPbeta (Fig. 3C and data not shown).
###end p 37
###begin p 38
###xml 384 387 377 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 454 457 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 507 514 496 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 665 667 650 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 668 669 653 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 668 669 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 809 814 786 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 823 828 796 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 837 846 806 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 895 898 864 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 925 928 894 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 945 952 914 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329,331</sup>
###xml 1007 1014 976 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 1122 1124 1091 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1125 1126 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1125 1126 1094 1095 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 1170 1175 1131 1136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 1237 1242 1194 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 1258 1267 1211 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 1275 1281 1228 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1283 1300 1236 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">Supplemental Data</xref>
###xml 1439 1444 1384 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 1492 1497 1433 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 1509 1518 1446 1455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 1520 1526 1457 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 1683 1689 1616 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 1721 1726 1650 1655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 1775 1780 1700 1705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 1792 1801 1713 1722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 1803 1809 1724 1730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 1909 1911 1830 1832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1912 1913 1833 1834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1912 1913 1833 1834 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 1969 1974 1882 1887 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 2021 2026 1930 1935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 2038 2047 1943 1952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 2049 2055 1954 1960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 2057 2074 1962 1979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">Supplemental Data</xref>
###xml 2079 2085 1984 1990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 2118 2119 2023 2024 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2191 2197 2092 2098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 2211 2216 2108 2113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 2255 2260 2148 2153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 2272 2281 2161 2170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 2283 2289 2172 2178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 2417 2423 2302 2308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 2436 2441 2317 2322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 2489 2494 2366 2371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 2506 2515 2379 2388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 2517 2523 2390 2396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
We have previously established that while both prostacyclin analogues, such as Cicaprost, and NO-donors, such as SIN-1, were indeed capable of cross-desensitizing or impairing Gq/PLCbeta signaling by TPalpha, they did so by entirely independent mechanisms and at different, though adjacent, sites. Specifically, prostacyclin-desensitization occurs by direct PKA phosphorylation of Ser329 while NO-desensitization occurs through PKG phosphorylation of Ser331, both within the unique C-tail domain of TPalpha [20,21]. Hence, to further investigate the mechanism by which SIN-1 and Cicaprost impair signaling by TPalpha, we examined their effects on U46619-induced [Ca2+]i mobilization, Rho activation, F-actin polymerization and cofilin phosphorylation by TPalpha and its specific site directed variants TPalphaS329A, TPalphaS331A, TPalphaS329,331A defective in the Cicaprost-sensitive PKA (at Ser329), NO-sensitive PKG (at Ser331) or both (at Ser329,331) phosphorylation sites, as previously described by us [20,21]. Consistent with those previous studies, pre-incubation with SIN-1 specifically impaired U46619-induced [Ca2+]i mobilization in HEK.TPalpha and HEK.TPalphaS329A cells while having no affect on such signaling in HEK.TPalphaS331A and HEK.TPalphaS329,331A cells (Fig. 2; Supplemental Data). Moreover, both SIN-1 and the alternative NO-donor FK409 also specifically impaired U46619-induced RhoA activation by TPalpha and TPalphaS329A cells but had no affect on signaling by TPalphaS331A and TPalphaS329,331A (Fig. 5A). Additionally, SIN-1 and FK409 also impaired U46619-induced F-actin polymerization, at low agonist concentration, and cofilin phosphorylation by TPalpha (Fig. 4 and data not shown) and TPalphaS329A cells, but had no affect on signaling by TPalphaS331A and TPalphaS329,331A (Fig. 5B and data not shown). On the other hand, pre-stimulation with Cicaprost impaired U46619-induced [Ca2+]i mobilization and RhoA activation by TPalpha and TPalphaS331A while having no affect on signaling by TPalphaS329A and TPalphaS329,331A (Fig. 2; Supplemental Data and Fig. 5A). Consistent with this, the PGD2 receptor (DP) agonist BW245C also impaired RhoA activation by TPalpha (Fig. 3C) and TPalphaS331A without affecting signaling by TPalphaS329A and TPalphaS329,331A (Fig. 5A). Additionally, Cicaprost specifically impaired U46619-induced F-actin polymerization and cofilin phosphorylation by TPalpha (Fig. 4) and TPalphaS331A cells but had no affect on signaling by TPalphaS329A and TPalphaS329,331A (Fig. 5B and data not shown).
###end p 38
###begin p 39
###xml 76 78 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 79 80 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 79 80 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 103 105 100 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 311 313 301 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 431 438 418 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 559 561 543 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 562 563 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 562 563 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 770 773 750 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 855 858 835 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
Taken together these data clearly indicate that both Gq/PLCbeta-mediated [Ca2+]i mobilization and the G12/RhoGEF-dependent RhoA activation and cofilin phosphorylation by TPalpha are specifically impaired by the potent vasodilators SIN-1 and Cicaprost. On the other hand, neither agonist-induced Gq/PLCbeta nor G12/RhoA signaling by TPbeta is directly affected by either vasodilator. Moreover, consistent with our previous findings [20,21], our data herein further suggest that the mechanisms whereby Cicaprost and SIN-1 impair both the Gq/PLCbeta-mediated [Ca2+]i pathway and the Rho-dependent pathway are similar but entirely independent where NO/SIN-1-mediated desensitization occurs through a PKG-dependent mechanism involving direct phosphorylation of TPalpha at Ser331 while that of prostacyclin/Cicaprost involves a PKA-dependent mechanism where Ser329 is the phospho-target.
###end p 39
###begin title 40
###xml 55 60 <span type="species:ncbi:9606">human</span>
TPalpha- and TPbeta-mediated RhoA signaling in primary human AoSMCs
###end title 40
###begin p 41
###xml 235 239 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">[30]</xref>
###xml 445 451 419 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 530 536 498 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 620 626 587 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 762 768 729 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 849 855 810 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 897 898 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 973 979 934 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 1156 1162 1111 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 1309 1315 1258 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 1413 1419 1362 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
We next investigated TP-mediated Rho activation and cytoskeletal signaling in a physiologically relevant, vaso-responsive model by investigating U46619-induced signaling in 1degrees h.AoSMCs, cells that express both TPalpha and TPbeta [30]. Consistent with our findings herein in HEK.TPalpha and HEK.TPbeta cells, stimulation of 1degrees h.AoSMCs with U46619 led to rapid RhoA activation with maximal responses observed with 100-1000 nM U46619 (Fig. 6A). Stimulation of 1degrees h.AoSMCs also led to rapid F-actin polymerization (Fig. 6B) and cofilin phosphorylation with optimal responses generated using 1 muM U46619 (Fig. 6C). While the IP agonist Cicaprost did not lead to substantial RhoA activation and cofilin phosphorylation relative to the drug vehicle per se, it significantly impaired such U46619-mediated signaling in 1degrees h.AoSMCs (Fig. 7A). Consistent with this, the specific PGD2 receptor (DP) agonist BW245C also significantly impaired RhoA activation (Fig. 7C) and cofilin phosphorylation in 1degrees h.AoSMCs. Similarly, while the NO donors SIN-1 and FK409 alone did not induce substantial RhoA signaling relative to the drug vehicle per se, they each significantly impaired U46619-induced RhoA activation and cofilin phosphorylation following their pre-incubation in 1degrees h.AoSMCs (Fig. 7B and D). Moreover, while Cicaprost, Sin-1, BW245C or FK409 did not induce F-actin polymerization per se, they each significantly impaired U46619-induced F-actin polymerization (data not shown).
###end p 41
###begin p 42
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 151 152 151 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 792 799 764 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35 bib36" ref-type="bibr">[35,36]</xref>
###xml 1027 1031 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr">[36]</xref>
###xml 1167 1171 1120 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">[30]</xref>
Hence, taken together, both NO-donors and prostanoid vasodilatory agents, such as prostacyclin and PGD2 signaling through the prostacyclin (IP) and PGD2 (DP) receptors, respectively, can impair U46619-mediated Rho activation and cytoskeletal signaling in 1degrees h.AoSMCs. Moreover, our data generated in the HEK.TPalpha and HEK.TPbeta cell lines over-expressing the individual TPalpha and TPbeta isoforms, respectively, suggest that such inhibitory responses of prostacyclin and NO are mediated, at least in part, at the interface of the stimulatory GPCR (i.e. the TP). More specifically, by directly targeting TPalpha, prostacyclin and NO may impair its RhoA-signaling both at the level of TPalpha itself in addition to at the level of the well documented targets of cAMP/PKA and cGMP/PKG [35,36]. On the other hand, as TPbeta is not as such a direct target of prostacyclin- or NO-mediated phosphorylation and inhibition, their effect on TPbeta-mediated RhoA signaling may be solely manifest at a later point in the cascade [36]. Clarity on this issue in 1degrees h.AoSMCs is, however, confounded by the fact that h.AoSMCs express both TPalpha and TPbeta isoforms [30] and, therefore, it is possible that the vasodilatory agents NO and Cicaprost may target TPalpha, TPbeta or both in addition to other downstream targets.
###end p 42
###begin p 43
###xml 546 553 505 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 563 569 518 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 585 591 537 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 710 716 662 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 767 774 719 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 837 843 779 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 900 906 831 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 1012 1013 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1012 1013 936 937 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 1132 1138 1049 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 1198 1205 1111 1114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 1329 1335 1235 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 1354 1358 1260 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1371 1377 1274 1277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 1510 1516 1403 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 1523 1524 1416 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1523 1524 1416 1417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 1616 1622 1502 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
To address this issue, we generated small interfering RNA (siRNA)-targeting agents to selectively disrupt or knock-down expression of TPalpha and TPbeta in 1degrees h.AoSMCs. To begin with, the siRNA agents were validated by examining their ability to affect TPalpha and TPbeta expression and RhoA signaling in HEK.TPalpha and HEK.TPbeta cells. Under optimized experimental conditions, we observed effective isoform-specific knock-down of both TPalpha and TPbeta expression following 72 h incubation of HEK.TPalpha and HEK.TPbeta cells with siRNATPalpha and siRNATPbeta, respectively (Fig. 8A), with ~ 50-60% specific knock-down achieved as assessed by densitometry and radioligand binding assay in each case (Fig. 8A and data not shown). On the other hand, the siRNATPalpha did not affect TPbeta expression in HEK.TPbeta cells and siRNATPbeta did not affect TPalpha expression in HEK.TPalpha cells (Fig. 8A) thereby confirming the specificity of the TPalpha and TPbeta isoform-directed siRNAs. Additionally, RNAi directed to Lamin A/C, acting as a control, had no effect on either TPalpha or TPbeta expression in either cell line (Fig. 8A). Moreover, pre-incubation of HEK.TPalpha cells with siRNATPalpha significantly impaired U46619-induced RhoA activation but had no significant effect on such signaling in HEK.TPbeta cells (Fig. 8B). Conversely the anti-TPbeta siRNATPbeta significantly impaired U46619-induced RhoA activation in HEK.TPbeta cells but had no effect on such signaling in HEK.TPalpha cells (Fig. 8B). RNAi directed to Lamin A/C had no effect on either TPalpha- or TPbeta-mediated RhoA activation (Fig. 8B). Consistent with these findings, siRNAs directed to TPalpha and TPbeta also impaired U46619-mediated F-actin polymerization and cofilin phosphorylation in HEK.TPalpha and HEK.TPbeta cells, respectively, and in an entirely isoform specific manner (data not shown).
###end p 43
###begin p 44
###xml 379 386 366 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 447 453 423 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 503 509 469 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 759 760 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 759 760 712 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 814 820 767 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 885 892 832 835 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 902 908 845 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
Having established the specificity of the siRNA reagents to impair expression and RhoA-dependent signaling by both TPalpha and TPbeta in HEK 293 cells, we next examined their ability to affect expression and signaling by the individual TP isoforms in h.AoSMCs. The effective delivery and utility of the latter siRNAs in 1degrees h.AoSMCs was initially confirmed whereby the siRNATPalpha impaired expression of TPalpha but not of TPbeta while siRNATPbeta reduced expression of TPbeta but not of TPalpha (Fig. 9A). Consistent with the reduced expression of TPalpha and TPbeta following incubation of the 1degrees h.AoSMCs with the isoform-specific siRNAs, there were reductions in U46619-induced Rho activation and cofilin phosphorylation in the presence of RNAi directed to either TP but not directed to Lamin A/C (Fig. 9B). Moreover, incubation of the 1degrees h.AoSMCs with both siRNATPalpha and siRNATPbeta led to a further significant reduction in U46619-induced Rho activation and cofilin phosphorylation. Hence, these data clearly suggest that both TPalpha and TPbeta contribute to the Rho activation in h.AoSMCs.
###end p 44
###begin p 45
###xml 327 333 321 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 400 406 388 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 441 447 425 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 493 499 477 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 802 809 777 780 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 819 825 790 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 919 925 890 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 1054 1061 1022 1025 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 1090 1096 1054 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 1185 1191 1149 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 1223 1229 1187 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 1275 1281 1233 1236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 1433 1440 1388 1391 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
We next examined the effect of the inhibitory vasodilatory agents SIN-1 and Cicaprost on U46619-mediated RhoA activation and signaling in 1degrees h.AoSMCs in the presence of the respective TP-isoform specific siRNA reagents. In the absence of siRNA, SIN-1 and Cicaprost significantly impaired U46619-mediated RhoA activation (Fig. 9C) consistent with our earlier findings in both 1degrees h.AoSMCs (Fig. 7A and B) and in HEK.TPalpha cells (Fig. 3B and C). Following 72 h incubation with siRNATPbeta, the NO donor SIN-1 specifically impaired U46619-mediated RhoA activation in h.AoSMCs to levels greater than that observed in vehicle treated cells. On the other hand, the inhibitory effect of SIN-1 on U46619-mediated RhoA activation in 1degrees h.AoSMCs was significantly less in the presence of siRNATPalpha at 72 h (Fig. 9C). Similarly, SIN-1 impaired U46619-mediated cofilin phosphorylation in the presence of siRNATPbeta to levels similar to those observed in vehicle-treated cells but its ability to impair U46619-signaling in the presence of siRNATPalpha was almost fully abolished (Fig. 9D). Moreover, the prostacyclin analogue Cicaprost significantly impaired Rho activation (Fig. 9C) and cofilin phosphorylation (Fig. 9D) in 1degrees h.AoSMCs pre-treated with siRNATPbeta to levels similar to that observed in the control, vehicle-treated cells while its ability to impair that signaling in cells pre-treated with the siRNATPalpha was almost completely abolished.
###end p 45
###begin p 46
Hence, we conclude that, similar to that which occurs for TP-mediated Gq/PLCbeta activation, both the NO and prostacyclin analogues SIN-1 and Cicaprost impair TP-mediated cytoskeletal changes involving RhoA activation and cofilin phosphorylation in 1degrees h.AoSMCs and that they do so, at least in part, by specifically and directly targeting TPalpha, impairing its downstream signaling. On the other hand, neither vasodilatory agent directly target TPbeta. Hence, TPalpha- and TPbeta-mediated RhoA signaling functionally diverge at the point at which prostacyclin and NO affect the RhoA signaling cascade.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 227 230 227 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib5" ref-type="bibr">[5]</xref>
###xml 352 354 352 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 413 415 413 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 452 461 452 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2 bib5 bib6" ref-type="bibr">[1,2,5,6]</xref>
###xml 596 597 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 599 601 599 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 617 619 617 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 622 624 622 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 660 665 660 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib8" ref-type="bibr">[1,8]</xref>
Much of the molecular events that underlie the complex physiologic processes of platelet aggregation and thrombosis, VSM contraction, migration, proliferation involve the fundamental reorganization of the cellular cytoskeleton [5]. A key step in this cytoskeletal reorganization involves alterations in MLC phosphorylation that occurs either through Ca2+-dependent activation of MLCK or through the alternative Ca2+-independent pathway, involving RhoA [1,2,5,6]. For example, the processes that contribute to platelet activation and secretion and shape change are under the dual control of the Gq/Ca2+-dependent and G12/Ca2+-independent pathways, respectively [1,8].
###end p 48
###begin p 49
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 310 317 310 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib37 bib38 bib39" ref-type="bibr">[37&#8211;39]</xref>
###xml 350 351 350 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 648 651 648 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
###xml 667 668 667 668 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 739 749 732 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13 bib15 bib22" ref-type="bibr">[13,15,22]</xref>
###xml 817 818 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 933 946 926 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16 bib17 bib19 bib22" ref-type="bibr">[16,17,19,22]</xref>
###xml 656 662 <span type="species:ncbi:9606">humans</span>
###xml 822 828 <span type="species:ncbi:9606">humans</span>
The prostanoid TXA2 plays an essential role within the vasculature inducing a range of cellular responses including platelet shape change and aggregation; contraction of vascular and bronchial smooth muscle (SM) cells; mitogenic and hypertrophic growth of VSM cells; inhibition of angiogenesis/vascularization [37-39]. Elevations in the levels of TXA2, its synthase or its receptor have been implicated in various cardiovascular disorders including thrombosis, myocardial infarction, unstable angina, atherosclerosis, systemic- and pregnancy-induced hypertension and ischemic heart disease, processes in which RhoA dysfunction is widely implicated [7]. In humans, TXA2 signals through 2 distinct isoforms referred to as TPalpha and TPbeta [13,15,22]. While the functional requirement for two types of receptor for TXA2 in humans is unknown there is substantial evidence that they may have distinct physiologic/pathophysiologic roles [16,17,19,22].
###end p 49
###begin p 50
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 178 185 178 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib5 bib6" ref-type="bibr">[2,5,6]</xref>
###xml 528 539 521 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib6 bib35 bib36" ref-type="bibr">[1,6,35,36]</xref>
###xml 640 650 623 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21 bib27" ref-type="bibr">[20,21,27]</xref>
Bearing this in mind and the growing appreciation of the critical role of the RhoA-mediated Ca2+-independent pathways to both normal and disease-processes within the vasculature [2,5,6], the central aim of the current study was to investigate the ability of the individual TPalpha and TPbeta isoforms to regulate RhoA signaling. Moreover, in view of the critical involvement of inhibitory agents including prostacyclin and NO, that largely signal through cAMP and cGMP second messengers, in regulating RhoA-dependent mechanisms [1,6,35,36] coupled to their role in differentially regulating TPalpha and TPbeta-mediated Gq/PLCbeta signaling [20,21,27], we also sought to investigate the impact of both vasodilators on RhoA signaling through the individual TP isoforms.
###end p 50
###begin p 51
###xml 175 182 168 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 292 299 272 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26 bib30" ref-type="bibr">[26,30]</xref>
###xml 528 529 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 877 878 850 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 908 911 881 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib3" ref-type="bibr">[3]</xref>
###xml 1270 1272 1236 1238 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1287 1289 1249 1251 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1599 1608 1561 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib31 bib32 bib33" ref-type="bibr">[1,31&#8211;33]</xref>
###xml 1666 1668 1628 1630 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1754 1756 1712 1714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1764 1766 1718 1720 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1766 1771 1720 1725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G228A</sup>
###xml 1797 1808 1743 1754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209l,D277N</sup>
###xml 2019 2021 1951 1953 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 2028 2030 1956 1958 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 2185 2187 2110 2112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 2328 2333 2253 2258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib8" ref-type="bibr">[1,8]</xref>
###xml 2101 2106 <span type="species:ncbi:10090">mouse</span>
To this end, we investigated the ability of TPalpha and TPbeta to mediate RhoA signaling in established clonal HEK 293 cell lines that over-express the individual TP isoforms [20,21] and in cultured 1degrees AoSMCs, a physiologically relevant cell type that expresses both TPalpha and TPbeta [26,30]. Throughout these studies, TP-mediated RhoA signaling was determined by monitoring its activation-dependent interaction with the Rho-binding domain (RBD) of its effector rhotekin in GST-RBD pulldown assays in response to the TXA2 mimetic U46619. Moreover, we also investigated the ability of TPalpha and TPbeta to regulate events downstream of RhoA: effector coupling by monitoring U46619-induced F-actin polymerization and cofilin phosphorylation. The ubiquitously expressed actin-depolymerising factor cofilin readily undergoes Rho/Rho kinase-dependent phosphorylation at Ser3 either by the LIM kinase 1/2 [3] and was used herein as a monitor of events downstream of Rho kinase in the Rho signaling cascade. Our conclusions are several-fold. Both TPalpha and TPbeta expressed in HEK 293 cells readily induced RhoA activation, F-actin polymerization and cofilin phosphorylation in response to U46619. In general, GPCR-mediated RhoA activation largely occurs through a G12, mainly Galpha13, -dependent mechanism but in certain settings, particularly at higher agonist concentrations, may also occur through a Gq-mechanism through the specific involvement of the LARG (Leukemia-associated Rho guanine-nucleotide exchange factor), but not the p115- or PDZ-, member of the RGS-containing RhoGEF family [1,31-33]. Hence, herein, we sought to clarify the involvement of G12 and Gq on TP-mediated RhoA signaling and found that dominant negative forms of Galpha12 (Galpha12G228A), not of Galphaq (GalphaqQ209l,D277N), significantly impaired U46619-mediated RhoA activation and cofilin phosphorylation. Collectively, these data confirmed that both TPalpha and TPbeta can independently couple to Gq/PLCbeta activation and Galpha12/Galpha13/RhoGEF-RhoA activation and are in agreement with a host of studies in mouse platelets whereby the single TP in that species couples to Gq/PLCbeta and to G12/RhoA activation to independently regulate platelet activation (aggregation and secretion) and platelet shape change responses, respectively [1,8].
###end p 51
###begin p 52
###xml 194 204 194 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21 bib27" ref-type="bibr">[20,21,27]</xref>
###xml 229 231 226 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 232 233 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 232 233 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 781 784 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 792 795 764 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 843 850 815 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 937 942 905 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 951 956 915 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 965 974 925 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 1047 1050 1003 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 1077 1080 1033 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 1097 1104 1053 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329,331</sup>
###xml 1127 1134 1083 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 1286 1288 1242 1244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1289 1290 1245 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1289 1290 1245 1246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 1326 1331 1274 1279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 1375 1380 1319 1324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 1392 1401 1332 1341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 1441 1442 1381 1382 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1548 1550 1488 1490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1551 1552 1491 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1551 1552 1491 1492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 1588 1593 1520 1525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 1635 1640 1563 1568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 1652 1661 1576 1585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 1729 1731 1650 1652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1732 1733 1653 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1732 1733 1653 1654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 1752 1754 1673 1675 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 2307 2315 2221 2229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib6 bib36" ref-type="bibr">[1,6,36]</xref>
###xml 2521 2526 2427 2432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 2538 2547 2440 2449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 2602 2607 2500 2505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 2619 2628 2513 2522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329,331A</sup>
###xml 2887 2890 2773 2776 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 2918 2921 2804 2807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 3086 3088 2972 2974 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 3438 3445 3307 3314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20 bib21" ref-type="bibr">[20,21]</xref>
###xml 3654 3658 3520 3524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr">[36]</xref>
Thereafter, we investigated the effect of the selective prostacyclin analogue Cicaprost and the NO donor SIN-1 on TP-mediated RhoA activation and signaling. Consistent with our previous reports [20,21,27], Gq/PLCbeta-mediated [Ca2+]i mobilization by TPalpha, but not by TPbeta, was desensitized in response to both Cicaprost and NO stimulation. In keeping with this, TPalpha-mediated RhoA activation, F-actin polymerization and cofilin phosphorylation was also specifically impaired by Cicaprost and SIN-1 while neither agent affected Rho-mediated signaling by TPbeta. As stated, while both prostacyclin and NO desensitize TPalpha-mediated Gq/PLCbeta signaling, they do so by entirely independent mechanisms involving direct PKA- and PKG- mediated phosphorylation of TPalpha at Ser329 and Ser331, respectively, within its unique C-tail domain [20,21]. Hence, we next compared the effect of SIN-1 and Cicaprost on Rho-signaling by TPalphaS329A, TPalphaS331A, TPalphaS329,331A, variants of TPalpha defective in the prostacyclin-sensitive PKA (at Ser329), NO-sensitive PKG (at Ser331) or both (at Ser329,331) phospho-target sites [20,21]. While SIN-1 and the alternative NO-donor FK409 impaired U46619-induced RhoA activation, cofilin phosphorylation, F-actin polymerization as well as [Ca2+]i mobilization by TPalpha and TPalphaS329A, they had no affect on signaling by TPalphaS331A and TPalphaS329,331A. Conversely, both Cicaprost and the PGD2 receptor agonist BW245C impaired RhoA activation, cofilin phosphorylation, F-actin polymerization and [Ca2+]i mobilization by TPalpha and TPalphaS331A but had no affect on signaling by TPalphaS329A and TPalphaS329,331A. Collectively, these data suggest that both Gq/PLCbeta-mediated [Ca2+]i mobilization and G12/RhoGEF -dependent RhoA activation of its effector rhotekin and cofilin phosphorylation by TPalpha, but not by TPbeta, are specifically impaired by the potent vasodilators SIN-1 and Cicaprost in this cellular context, at least. Of course the inhibitory effects of both prostacyclin and NO, and other agents that signal through cAMP and cGMP, on RhoA signaling are widely documented and form an essential component of the homeostatic regulatory mechanism that determines the balance between activation and inhibition, particularly within the vasculature [1,6,36]. Hence, it is arguable that the effects of Cicaprost and SIN-1 on TPalpha-mediated Rho signaling in HEK 293 cells are perhaps somewhat predictable. However, the fact that RhoA-mediated signaling by TPalphaS331A and TPalphaS329,331A is unaffected by SIN-1 while that signaling by TPalphaS329A and TPalphaS329,331A is unaffected by Cicaprost clearly suggest that the observed effects of SIN-1 and Cicaprost on TPalpha, in the HEK 293 over-expression system at least, are due to direct effects on TPalpha itself, namely through site specific prostacyclin-induced PKA (at Ser329) and NO-induced PKG (at Ser331) phosphorylation rather than at some other intermediary in the RhoA signaling cascade. Moreover, in keeping with that hypothesis, the finding that agonist-induced G12/RhoA signaling by TPbeta is not affected by either prostacyclin or NO again suggests that the effects of both vasodilators are due to direct effects on TPalpha itself and is entirely consistent with previous findings involving both prostacyclin- and NO-mediated desensitization of TPalpha and TPbeta signaling through the Gq/PLCbeta effector system [20,21]. The fact that we do not observe any measurable inhibitory effects on TPbeta-mediated RhoA signaling by either Cicaprost or SIN-1, such as might be expected to occur at a later point in the signaling cascade [36], could in theory be due to the fact that the level of TP receptor expression in the HEK 293 stable cell lines produces an overriding forward signal, overwhelming any inhibitory effects of prostacyclin or NO.
###end p 52
###begin p 53
###xml 672 673 660 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 851 862 833 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6 bib8 bib35 bib36" ref-type="bibr">[6,8,35,36]</xref>
###xml 1222 1229 1193 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35 bib36" ref-type="bibr">[35,36]</xref>
###xml 1285 1292 1249 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26 bib30" ref-type="bibr">[26,30]</xref>
###xml 1692 1696 1636 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr">[36]</xref>
###xml 1779 1786 1723 1726 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 1796 1802 1736 1739 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 2109 2116 2033 2036 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 2177 2183 2090 2093 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 3006 3007 2856 2857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 3006 3007 2856 2857 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 3462 3469 3292 3295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 3541 3547 3367 3370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 151 156 <span type="species:ncbi:9606">human</span>
###xml 1231 1236 <span type="species:ncbi:9606">Human</span>
Therefore, we extended our studies by investigating TP-mediated Rho activation and cytoskeletal signaling in the more physiologically relevant primary human aortic smooth muscle cells. As expected, stimulation of cultured 1degrees h.AoSMCs with U46619 led to a concentration-dependent RhoA activation, F-actin polymerization and cofilin phosphorylation. Moreover, Cicaprost (IP agonist) and BW245C (DP agonist) and the NO donors SIN-1 and FK409 each significantly impaired such U46619-induced RhoA activation, F-actin polymerization and cofilin phosphorylation in 1degrees h.AoSMCs. Hence, collectively, both NO-donors and the vasodilatory prostanoids prostacyclin and PGD2 readily desensitize TP-mediated Rho activation and cytoskeletal signaling in 1degrees h.AoSMCs, findings entirely predicted from and in keeping with outcomes from other systems [6,8,35,36]. However, as stated, our data generated in the HEK 293 cell lines over-expressing the individual TPalpha and TPbeta isoforms suggest that such inhibitory responses of prostacyclin and NO are mediated, at least in part, directly at the level of TPalpha itself rather than at the level of other well documented targets of cAMP/PKA and cGMP/PKG on Rho signaling [35,36]. Human AoSMCs express both TPalpha and TPbeta isoforms [26,30]. Hence, through the use of TP isoform-specific siRNA, we sought to determine whether TPalpha and TPbeta independently contribute to U46619-induced RhoA activation and signaling in 1degrees h.AoSMCs and to ascertain whether the inhibitory effects of NO and/or Cicaprost may directly target TPalpha, or indeed TPbeta, at the level of the receptor itself and/or in addition to other downstream targets [36]. Under optimized experimental conditions, the specificity and utility of the siRNATPalpha and siRNATPbeta reagents were validated whereby we observed effective isoform-specific knock-down of both TPalpha and TPbeta expression and RhoA-mediated signaling in their respective HEK 293 cell lines. Moreover, the effective delivery and utility of the latter siRNAs in 1degrees h.AoSMCs was confirmed whereby the siRNATPalpha reduced expression of TPalpha but not of TPbeta, while siRNATPbeta reduced expression of TPbeta but not of TPalpha. It was notable that the level of siRNA-mediated impairment of TPalpha and TPbeta expression in the 1degrees h.AoSMCs was significantly higher than observed in HEK.TPalpha or HEK.TPbeta cells. The reason for this apparent discrepancy is simply owing to the fact that the stably transfected HEK 293 cell lines express TPalpha and TPbeta in abundance (~ 2 pmol/mg protein) relative to that expressed in 1degrees h.AoSMCs (20-50 fmol/mg protein) and hence, the inability of the siRNA to completely konckdown TPalpha or TPbeta expression in HEK.TPalpha or HEK.TPbeta cells was not surprising. Consistent with their reduced expression in the 1degrees h.AoSMCs, there was a significant reduction in U46619-mediated Rho activation and cofilin phosphorylation in the presence of RNAi directed to either TPalpha or TPbeta but not to Lamin A/C confirming that both TPalpha and TPbeta contribute to the RhoA activation in h.AoSMCs. While SIN-1 and Cicaprost significantly impaired U46619-mediated RhoA activation in the presence of the siRNA directed to Lamin A/C to levels similar to that in vehicle-treated cells, the inhibitory action of both agents on RhoA activation and cofilin phosphorylation in 1degrees h.AoSMCs exposed to the siRNATPalpha was substantially impaired. On the other hand, in the presence of siRNATPbeta both SIN-1 and Cicaprost reduced U46619-mediated RhoA, F-actin polymerization (data not shown) and cofilin phosphorylation to levels not significantly different to those observed in vehicle-treated cells. Hence, both the NO and prostacyclin impair TP-mediated cytoskeletal changes involving RhoA activation, F-actin polymerization and cofilin phosphorylation in 1degrees h.AoSMCs and they do so, at least in part, by specifically and directly targeting TPalpha impairing its downstream signaling. On the other hand, neither vasodilatory agent directly target TPbeta.
###end p 53
###begin p 54
###xml 195 202 195 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35 bib36" ref-type="bibr">[35,36]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib40" ref-type="bibr">[40]</xref>
###xml 502 514 502 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6 bib36 bib41 bib42" ref-type="bibr">[6,36,41,42]</xref>
###xml 660 662 657 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 739 741 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 800 802 797 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 825 829 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr">[35]</xref>
###xml 983 995 980 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6 bib35 bib36 bib43" ref-type="bibr">[6,35,36,43]</xref>
###xml 1150 1153 1147 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
###xml 1186 1199 1183 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36 bib42 bib44 bib45" ref-type="bibr">[36,42,44,45]</xref>
###xml 1238 1241 1235 1238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
###xml 1557 1564 1554 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36 bib46" ref-type="bibr">[36,46]</xref>
###xml 1683 1691 1680 1688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1696 1703 1693 1700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1732 1735 1729 1732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
###xml 1904 1908 1901 1905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib47" ref-type="bibr">[47]</xref>
###xml 1952 1955 1949 1952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
###xml 2356 2359 2346 2349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
###xml 2619 2622 2605 2608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 2630 2633 2616 2619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 2739 2742 2721 2724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
###xml 3082 3086 3061 3065 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S188</sup>
###xml 3129 3133 3108 3112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib47" ref-type="bibr">[47]</xref>
As stated, it is widely held that agents that signal through either cAMP- or cGMP-second messenger systems play a critical counter-balancing/inhibitory affect on RhoA-mediated signaling cascades [35,36] as well as regulating Rho-mediated transcriptional responses through the serum response factor [40]. In fact within the vasculature, there is a critical reciprocal relationship between RhoA signaling and expression and that of NO-signaling and expression of endothelial nitric oxide synthase (eNOS) [6,36,41,42]. Moreover, in platelets there is a differential effect whereby cAMP/PKA inhibits both the Gq/PLCbeta-mediated aggregation and secretion and the G12/Rho-mediated shape change while cGMP/PKG signaling inhibits the former Gq/Ca2+ dependent mechanism but does not affect the latter RhoA/Ca2+ independent mechanism [35]. Clearly many of the actions of cAMP and cGMP on RhoA signaling are mediated through their respective second messenger kinases PKA and PKG, respectively [6,35,36,43] and more recently it has been established that this may largely occur through their direct phosphorylation of RhoA itself at an identical site, namely Ser188 within its hypervariable region [36,42,44,45]. Whilst phosphorylation of RhoA at Ser188 does not apparently alter its association with either RhoGEFs or RhoGAPs (GTPase activating proteins), it significantly increases its interaction with RhoGDI (GDP dissociation inhibitor) thereby reducing the level of membrane bound RhoA and impairing its ability to activate its key effectors including Rho Kinases [36,46]. Moreover, in a recent study investigating NGF-mediated RhoA responses in neuronal PC12 cells, Nusser et al. provided in vitro and in vivo evidence to suggest that Ser188 phosphorylation of RhoA impairs activation of Rho kinase (ROCK 1/2), but does not affect its ability to activate other Rho effectors including rhotekin, mDia-1 and PKN [47]. From their studies, they proposed that Ser188 phosphorylation of RhoA may act as a 'secondary molecular switch' capable of overriding GTP-elicited activation of certain RhoA effectors, such as ROCK, but directing it to signal with (an)other subset of Rho effectors, perhaps in a cell specific manner. Returning to studies herein on TPalpha- and TPbeta-mediated RhoA signalling, both NO and prostacyclin directly target RhoA phosphorylation at Ser188 through their regulation of PKG and PKA signaling, respectively (data not shown). Hence, RhoA-mediated signaling by TPalpha is subject to regulation by both direct prostacyclin/PKA and NO/PKG-inhibition mediated through their respective phosphorylation of Ser329 and Ser331 within the unique C-tail domain of TPalpha in addition to the more general type of regulation through Ser188 phosphorylation of RhoA. On the other hand, TPbeta is not a direct target for either PKA or PKG phosphorylation or inhibition, but its RhoA-mediated signaling would be sensitive to RhoA phosphorylation by either second messenger kinase. Whilst it has not as yet been established whether the "molecular switch mechanism" resulting from RhoAS188 phosphorylation proposed by Nusser et al. [47] to exist in neuronal cells can be extended to other cell/tissue types, such as smooth muscle, it is tempting to speculate.
###end p 54
###begin p 55
###xml 34 41 34 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig10" ref-type="fig">Fig. 10</xref>
###xml 496 502 489 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser188</sup>
###xml 538 539 531 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 755 762 745 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig10" ref-type="fig">Fig. 10</xref>
###xml 793 797 783 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib47" ref-type="bibr">[47]</xref>
Hence, as presented in our model (Fig. 10), we propose that as TPalpha is directly targeted for inhibition by prostacyclin and NO, its signaling would be fully impaired by either vasodilator beginning at the level of the receptor itself. On the other hand, as TPbeta is not subject to direct PKA or PKG phosphorylation, its signaling by prostacyclin or NO may only be regulated at downstream intermediary level(s), such as at the level of RhoA phosphorylation. In the event that the 'phospho-RhoASer188 switch mechanism' exists within TXA2-responsive VSM or indeed in platelets, RhoA signaling through TPbeta may be directed away from one effector system, such as ROCK signaling, in the direction of another effector(s), such as rhotekin, mDia-1 and PKN (Fig. 10) as proposed by Nusser et al. [47] in the neuronal system, or indeed toward other subset(s) of the many diverse RhoA effectors, perhaps in a cell specific manner. Final clarification as to whether such a mechanism exists will require further detailed investigation.
###end p 55
###begin p 56
###xml 344 346 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 362 364 348 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 372 374 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1076 1077 1045 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1119 1128 1088 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib48 bib49" ref-type="bibr">[2,48,49]</xref>
###xml 1458 1461 1421 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">[2]</xref>
###xml 821 826 <span type="species:ncbi:9606">human</span>
Hence, in summary TPalpha- and TPbeta-mediated RhoA signaling functionally diverge at the point at which prostacyclin and NO affect the RhoA signaling cascade. These data further support the hypothesis that TPalpha is the major regulatory TP isoform involved in vascular hemostasis being a direct target for inhibition of both its Gq/PLCbeta/Ca2+-dependent and G12/RhoA/Ca2+-independent signaling by prostacyclin and NO within the vasculature. On the other hand, as TPbeta remains unaffected by either agent, at the interface of the receptor at least, the functional role of TPbeta remains to be further clearly defined. The data herein highlight further critical differences between the TPalpha and TPbeta receptor isoforms in terms of their regulation of Rho signaling that are likely to be physiologically relevant in human tissues such as SM and suggest that selective targeting and impairment of TPalpha-mediated signaling may offer a useful therapeutic approach in the treatment of certain vascular diseases such as systemic- and pulmonary-hypertension in which both TXA2 and RhoA dysfunction has been implicated [2,48,49]. Moreover, the data also suggests that for effective impairment of TPbeta-mediated RhoA activation and signaling in such clinical settings, it may be necessary to fully antagonize it at the level of the TPbeta receptor itself rather than at a later downstream step, such as most typically at the level Rho kinase/ROCK inhibition [2].
###end p 56
###begin title 57
Supplemental figures
###end title 57
###begin p 58
###xml 0 8 0 8 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</label>
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 535 537 519 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 549 551 529 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 644 646 620 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 715 717 689 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 762 764 730 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 799 801 761 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 836 838 792 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 873 875 823 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 910 912 854 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 946 948 884 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 8 971 8 907 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="59">Cicaprost- and SIN-1-induced Desesitization of TP-mediated [Ca<sup>2+</sup>]<italic>i</italic> Mobilization. HEK.TP&#945; (i-iii) and HEK.TP&#946; (iv-vi) cells, transiently co-transfected with pCMV:G&#945;q and preloaded with Fura2/AM, were stimulated with 1 &#956;M U46619 (i and iv) or 1 &#956;M Cicaprost followed by 1 &#956;M U46619 (ii and v) or 10 &#956;M SIN-1 followed by 1 &#956;M U46619 (iii and vi), where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments and are plotted as changes in [Ca<sup>2+</sup>]i (&#916;[Ca<sup>2+</sup>]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as &#916;[Ca<sup>2+</sup>]i (means &#177; S.E.M; n=4). Actual mean changes in U46619-mediated [Ca<sup>2+</sup>]i (nM &#177; S.E.) were as follows: i, &#916;[Ca<sup>2+</sup>]i = 188.1 &#177; 6.4 nM; ii, &#916;[Ca<sup>2+</sup>]i = 132 &#177; 12.7 nM; iii, &#916;[Ca<sup>2+</sup>]i = 87.4 &#177; 12.5 nM; iv, &#916;[Ca<sup>2+</sup>]i = 191.1 &#177; 16.3 nM; v, &#916;[Ca<sup>2+</sup>]i = 212 &#177; 16.2 nM; vi, &#916;[Ca<sup>2+</sup>]i = 167.5 &#177; 11.3 nM.</p>
###xml 8 971 8 907 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="59">Cicaprost- and SIN-1-induced Desesitization of TP-mediated [Ca<sup>2+</sup>]<italic>i</italic> Mobilization. HEK.TP&#945; (i-iii) and HEK.TP&#946; (iv-vi) cells, transiently co-transfected with pCMV:G&#945;q and preloaded with Fura2/AM, were stimulated with 1 &#956;M U46619 (i and iv) or 1 &#956;M Cicaprost followed by 1 &#956;M U46619 (ii and v) or 10 &#956;M SIN-1 followed by 1 &#956;M U46619 (iii and vi), where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments and are plotted as changes in [Ca<sup>2+</sup>]i (&#916;[Ca<sup>2+</sup>]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as &#916;[Ca<sup>2+</sup>]i (means &#177; S.E.M; n=4). Actual mean changes in U46619-mediated [Ca<sup>2+</sup>]i (nM &#177; S.E.) were as follows: i, &#916;[Ca<sup>2+</sup>]i = 188.1 &#177; 6.4 nM; ii, &#916;[Ca<sup>2+</sup>]i = 132 &#177; 12.7 nM; iii, &#916;[Ca<sup>2+</sup>]i = 87.4 &#177; 12.5 nM; iv, &#916;[Ca<sup>2+</sup>]i = 191.1 &#177; 16.3 nM; v, &#916;[Ca<sup>2+</sup>]i = 212 &#177; 16.2 nM; vi, &#916;[Ca<sup>2+</sup>]i = 167.5 &#177; 11.3 nM.</p></caption>
###xml 971 971 907 907 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gr11"/>
###xml 0 971 0 907 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="N0x19d4360N0x2cb4e90" position="anchor"><label>Figure 1</label><caption><p textid="59">Cicaprost- and SIN-1-induced Desesitization of TP-mediated [Ca<sup>2+</sup>]<italic>i</italic> Mobilization. HEK.TP&#945; (i-iii) and HEK.TP&#946; (iv-vi) cells, transiently co-transfected with pCMV:G&#945;q and preloaded with Fura2/AM, were stimulated with 1 &#956;M U46619 (i and iv) or 1 &#956;M Cicaprost followed by 1 &#956;M U46619 (ii and v) or 10 &#956;M SIN-1 followed by 1 &#956;M U46619 (iii and vi), where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments and are plotted as changes in [Ca<sup>2+</sup>]i (&#916;[Ca<sup>2+</sup>]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as &#916;[Ca<sup>2+</sup>]i (means &#177; S.E.M; n=4). Actual mean changes in U46619-mediated [Ca<sup>2+</sup>]i (nM &#177; S.E.) were as follows: i, &#916;[Ca<sup>2+</sup>]i = 188.1 &#177; 6.4 nM; ii, &#916;[Ca<sup>2+</sup>]i = 132 &#177; 12.7 nM; iii, &#916;[Ca<sup>2+</sup>]i = 87.4 &#177; 12.5 nM; iv, &#916;[Ca<sup>2+</sup>]i = 191.1 &#177; 16.3 nM; v, &#916;[Ca<sup>2+</sup>]i = 212 &#177; 16.2 nM; vi, &#916;[Ca<sup>2+</sup>]i = 167.5 &#177; 11.3 nM.</p></caption><graphic xlink:href="gr11"/></fig>
###xml 971 979 907 915 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</label>
###xml 1034 1036 970 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1037 1038 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1111 1116 1039 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 1137 1142 1061 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 1167 1176 1087 1096 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331,329A</sup>
###xml 1627 1629 1538 1540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1639 1641 1546 1548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1734 1736 1637 1639 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1810 1812 1707 1709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1857 1859 1748 1750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1894 1896 1779 1781 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1931 1933 1810 1812 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1968 1970 1841 1843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2004 2006 1871 1873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2040 2042 1901 1903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2076 2078 1931 1933 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2113 2115 1962 1964 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2150 2152 1993 1995 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2185 2187 2022 2024 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2223 2225 2054 2056 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2262 2264 2087 2089 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 979 2286 915 2109 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="60">Cicaprost- and SIN-1- Desensitization of TP-induced [Ca<sup>2+</sup>]<italic>i</italic> Mobilization in HEK 293 cells. Panel A: HEK.TP&#945; (i-iii), HEK.TP&#945;<sup>S329A</sup> (iv-vi), HEK.TP&#945;<sup>S331A</sup> (vii-ix) and HEK.TP&#945;<sup>S331,329A</sup> (x &#8211;xii) cells, transiently co-transfected with pCMV:G&#945;q and preloaded with Fura2/AM, were stimulated with either 1 &#956;M U46619 (i, iv, vii, x), 1 &#956;M Cicaprost followed by 1 &#956;M U46619 (ii, v, vii, xi ) or 10 &#956;M SIN-1 followed by 1 &#956;M U46619 (iii, vi, viii, xii) where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments, and are plotted as changes in intracellular Ca<sup>2+</sup> (&#916;[Ca<sup>2+</sup>]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as &#916;[Ca<sup>2+</sup>]i (means &#177; S.E.M; n=4). Actual mean changes in U46619-mediated &#916;[Ca<sup>2+</sup>]i (nM &#177; S.E.) were as follows: i, &#916;[Ca<sup>2+</sup>]i = 188.1 &#177; 6.4 nM; ii, &#916;[Ca<sup>2+</sup>]i = 132 &#177; 12.7 nM; iii, &#916;[Ca<sup>2+</sup>]i = 87.4 &#177; 12.5 nM; iv, &#916;[Ca<sup>2+</sup>]i = 155.6 &#177; 4.4 nM; v, &#916;[Ca<sup>2+</sup>]i = 146 &#177; 19.3 nM; vi, &#916;[Ca<sup>2+</sup>]i = 77 &#177; 20.2 nM; vii, &#916;[Ca<sup>2+</sup>]i = 201 &#177; 9.1 nM; viii, &#916;[Ca<sup>2+</sup>]i = 58.2 &#177; 18.4 nM; ix, &#916;[Ca<sup>2+</sup>]i = 181 &#177; 19.6 nM; x, &#916;[Ca<sup>2+</sup>]i = 198.4 &#177; 14.3 nM; xi, &#916;[Ca<sup>2+</sup>]i = 164.1 &#177; 15.6 nM; xii, &#916;[Ca<sup>2+</sup>]i = 193.6 &#177; 23.2 nM</p>
###xml 979 2286 915 2109 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="60">Cicaprost- and SIN-1- Desensitization of TP-induced [Ca<sup>2+</sup>]<italic>i</italic> Mobilization in HEK 293 cells. Panel A: HEK.TP&#945; (i-iii), HEK.TP&#945;<sup>S329A</sup> (iv-vi), HEK.TP&#945;<sup>S331A</sup> (vii-ix) and HEK.TP&#945;<sup>S331,329A</sup> (x &#8211;xii) cells, transiently co-transfected with pCMV:G&#945;q and preloaded with Fura2/AM, were stimulated with either 1 &#956;M U46619 (i, iv, vii, x), 1 &#956;M Cicaprost followed by 1 &#956;M U46619 (ii, v, vii, xi ) or 10 &#956;M SIN-1 followed by 1 &#956;M U46619 (iii, vi, viii, xii) where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments, and are plotted as changes in intracellular Ca<sup>2+</sup> (&#916;[Ca<sup>2+</sup>]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as &#916;[Ca<sup>2+</sup>]i (means &#177; S.E.M; n=4). Actual mean changes in U46619-mediated &#916;[Ca<sup>2+</sup>]i (nM &#177; S.E.) were as follows: i, &#916;[Ca<sup>2+</sup>]i = 188.1 &#177; 6.4 nM; ii, &#916;[Ca<sup>2+</sup>]i = 132 &#177; 12.7 nM; iii, &#916;[Ca<sup>2+</sup>]i = 87.4 &#177; 12.5 nM; iv, &#916;[Ca<sup>2+</sup>]i = 155.6 &#177; 4.4 nM; v, &#916;[Ca<sup>2+</sup>]i = 146 &#177; 19.3 nM; vi, &#916;[Ca<sup>2+</sup>]i = 77 &#177; 20.2 nM; vii, &#916;[Ca<sup>2+</sup>]i = 201 &#177; 9.1 nM; viii, &#916;[Ca<sup>2+</sup>]i = 58.2 &#177; 18.4 nM; ix, &#916;[Ca<sup>2+</sup>]i = 181 &#177; 19.6 nM; x, &#916;[Ca<sup>2+</sup>]i = 198.4 &#177; 14.3 nM; xi, &#916;[Ca<sup>2+</sup>]i = 164.1 &#177; 15.6 nM; xii, &#916;[Ca<sup>2+</sup>]i = 193.6 &#177; 23.2 nM</p></caption>
###xml 2286 2286 2109 2109 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gr12"/>
###xml 971 2286 907 2109 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="N0x19d4360N0x2cb5070" position="anchor"><label>Figure 2</label><caption><p textid="60">Cicaprost- and SIN-1- Desensitization of TP-induced [Ca<sup>2+</sup>]<italic>i</italic> Mobilization in HEK 293 cells. Panel A: HEK.TP&#945; (i-iii), HEK.TP&#945;<sup>S329A</sup> (iv-vi), HEK.TP&#945;<sup>S331A</sup> (vii-ix) and HEK.TP&#945;<sup>S331,329A</sup> (x &#8211;xii) cells, transiently co-transfected with pCMV:G&#945;q and preloaded with Fura2/AM, were stimulated with either 1 &#956;M U46619 (i, iv, vii, x), 1 &#956;M Cicaprost followed by 1 &#956;M U46619 (ii, v, vii, xi ) or 10 &#956;M SIN-1 followed by 1 &#956;M U46619 (iii, vi, viii, xii) where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments, and are plotted as changes in intracellular Ca<sup>2+</sup> (&#916;[Ca<sup>2+</sup>]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as &#916;[Ca<sup>2+</sup>]i (means &#177; S.E.M; n=4). Actual mean changes in U46619-mediated &#916;[Ca<sup>2+</sup>]i (nM &#177; S.E.) were as follows: i, &#916;[Ca<sup>2+</sup>]i = 188.1 &#177; 6.4 nM; ii, &#916;[Ca<sup>2+</sup>]i = 132 &#177; 12.7 nM; iii, &#916;[Ca<sup>2+</sup>]i = 87.4 &#177; 12.5 nM; iv, &#916;[Ca<sup>2+</sup>]i = 155.6 &#177; 4.4 nM; v, &#916;[Ca<sup>2+</sup>]i = 146 &#177; 19.3 nM; vi, &#916;[Ca<sup>2+</sup>]i = 77 &#177; 20.2 nM; vii, &#916;[Ca<sup>2+</sup>]i = 201 &#177; 9.1 nM; viii, &#916;[Ca<sup>2+</sup>]i = 58.2 &#177; 18.4 nM; ix, &#916;[Ca<sup>2+</sup>]i = 181 &#177; 19.6 nM; x, &#916;[Ca<sup>2+</sup>]i = 198.4 &#177; 14.3 nM; xi, &#916;[Ca<sup>2+</sup>]i = 164.1 &#177; 15.6 nM; xii, &#916;[Ca<sup>2+</sup>]i = 193.6 &#177; 23.2 nM</p></caption><graphic xlink:href="gr12"/></fig>
Figure 1Cicaprost- and SIN-1-induced Desesitization of TP-mediated [Ca2+]i Mobilization. HEK.TPalpha (i-iii) and HEK.TPbeta (iv-vi) cells, transiently co-transfected with pCMV:Galphaq and preloaded with Fura2/AM, were stimulated with 1 muM U46619 (i and iv) or 1 muM Cicaprost followed by 1 muM U46619 (ii and v) or 10 muM SIN-1 followed by 1 muM U46619 (iii and vi), where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments and are plotted as changes in [Ca2+]i (Delta[Ca2+]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as Delta[Ca2+]i (means +/- S.E.M; n=4). Actual mean changes in U46619-mediated [Ca2+]i (nM +/- S.E.) were as follows: i, Delta[Ca2+]i = 188.1 +/- 6.4 nM; ii, Delta[Ca2+]i = 132 +/- 12.7 nM; iii, Delta[Ca2+]i = 87.4 +/- 12.5 nM; iv, Delta[Ca2+]i = 191.1 +/- 16.3 nM; v, Delta[Ca2+]i = 212 +/- 16.2 nM; vi, Delta[Ca2+]i = 167.5 +/- 11.3 nM.Figure 2Cicaprost- and SIN-1- Desensitization of TP-induced [Ca2+]i Mobilization in HEK 293 cells. Panel A: HEK.TPalpha (i-iii), HEK.TPalphaS329A (iv-vi), HEK.TPalphaS331A (vii-ix) and HEK.TPalphaS331,329A (x -xii) cells, transiently co-transfected with pCMV:Galphaq and preloaded with Fura2/AM, were stimulated with either 1 muM U46619 (i, iv, vii, x), 1 muM Cicaprost followed by 1 muM U46619 (ii, v, vii, xi ) or 10 muM SIN-1 followed by 1 muM U46619 (iii, vi, viii, xii) where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments, and are plotted as changes in intracellular Ca2+ (Delta[Ca2+]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as Delta[Ca2+]i (means +/- S.E.M; n=4). Actual mean changes in U46619-mediated Delta[Ca2+]i (nM +/- S.E.) were as follows: i, Delta[Ca2+]i = 188.1 +/- 6.4 nM; ii, Delta[Ca2+]i = 132 +/- 12.7 nM; iii, Delta[Ca2+]i = 87.4 +/- 12.5 nM; iv, Delta[Ca2+]i = 155.6 +/- 4.4 nM; v, Delta[Ca2+]i = 146 +/- 19.3 nM; vi, Delta[Ca2+]i = 77 +/- 20.2 nM; vii, Delta[Ca2+]i = 201 +/- 9.1 nM; viii, Delta[Ca2+]i = 58.2 +/- 18.4 nM; ix, Delta[Ca2+]i = 181 +/- 19.6 nM; x, Delta[Ca2+]i = 198.4 +/- 14.3 nM; xi, Delta[Ca2+]i = 164.1 +/- 15.6 nM; xii, Delta[Ca2+]i = 193.6 +/- 23.2 nM
###end p 58
###begin p 59
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 527 529 511 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 541 543 521 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 636 638 612 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 707 709 681 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 754 756 722 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 791 793 753 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 828 830 784 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 865 867 815 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 902 904 846 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 938 940 876 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Cicaprost- and SIN-1-induced Desesitization of TP-mediated [Ca2+]i Mobilization. HEK.TPalpha (i-iii) and HEK.TPbeta (iv-vi) cells, transiently co-transfected with pCMV:Galphaq and preloaded with Fura2/AM, were stimulated with 1 muM U46619 (i and iv) or 1 muM Cicaprost followed by 1 muM U46619 (ii and v) or 10 muM SIN-1 followed by 1 muM U46619 (iii and vi), where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments and are plotted as changes in [Ca2+]i (Delta[Ca2+]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as Delta[Ca2+]i (means +/- S.E.M; n=4). Actual mean changes in U46619-mediated [Ca2+]i (nM +/- S.E.) were as follows: i, Delta[Ca2+]i = 188.1 +/- 6.4 nM; ii, Delta[Ca2+]i = 132 +/- 12.7 nM; iii, Delta[Ca2+]i = 87.4 +/- 12.5 nM; iv, Delta[Ca2+]i = 191.1 +/- 16.3 nM; v, Delta[Ca2+]i = 212 +/- 16.2 nM; vi, Delta[Ca2+]i = 167.5 +/- 11.3 nM.
###end p 59
###begin p 60
###xml 55 57 55 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 132 137 124 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 158 163 146 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 188 197 172 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331,329A</sup>
###xml 648 650 623 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 660 662 631 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 755 757 722 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 831 833 792 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 878 880 833 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 915 917 864 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 952 954 895 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 989 991 926 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1025 1027 956 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1061 1063 986 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1097 1099 1016 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1134 1136 1047 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1171 1173 1078 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1206 1208 1107 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1244 1246 1139 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1283 1285 1172 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Cicaprost- and SIN-1- Desensitization of TP-induced [Ca2+]i Mobilization in HEK 293 cells. Panel A: HEK.TPalpha (i-iii), HEK.TPalphaS329A (iv-vi), HEK.TPalphaS331A (vii-ix) and HEK.TPalphaS331,329A (x -xii) cells, transiently co-transfected with pCMV:Galphaq and preloaded with Fura2/AM, were stimulated with either 1 muM U46619 (i, iv, vii, x), 1 muM Cicaprost followed by 1 muM U46619 (ii, v, vii, xi ) or 10 muM SIN-1 followed by 1 muM U46619 (iii, vi, viii, xii) where ligands were added at the times indicated by arrows. Data presented are representative of at least four independent experiments, and are plotted as changes in intracellular Ca2+ (Delta[Ca2+]i (nM)) as a function of time (s) following ligand stimulation. Data are plotted as Delta[Ca2+]i (means +/- S.E.M; n=4). Actual mean changes in U46619-mediated Delta[Ca2+]i (nM +/- S.E.) were as follows: i, Delta[Ca2+]i = 188.1 +/- 6.4 nM; ii, Delta[Ca2+]i = 132 +/- 12.7 nM; iii, Delta[Ca2+]i = 87.4 +/- 12.5 nM; iv, Delta[Ca2+]i = 155.6 +/- 4.4 nM; v, Delta[Ca2+]i = 146 +/- 19.3 nM; vi, Delta[Ca2+]i = 77 +/- 20.2 nM; vii, Delta[Ca2+]i = 201 +/- 9.1 nM; viii, Delta[Ca2+]i = 58.2 +/- 18.4 nM; ix, Delta[Ca2+]i = 181 +/- 19.6 nM; x, Delta[Ca2+]i = 198.4 +/- 14.3 nM; xi, Delta[Ca2+]i = 164.1 +/- 15.6 nM; xii, Delta[Ca2+]i = 193.6 +/- 23.2 nM
###end p 60
###begin title 61
Supplementary data
###end title 61
###begin p 62
Supplementary data associated with this article can be found, in the online version, at .
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
This work was supported by grants from The Wellcome Trust, The Health Research Board, Ireland and Science Foundation Ireland.
###end p 64
###begin title 65
References
###end title 65
###begin p 66
###xml 446 457 421 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209l,D277N</sup>
###xml 467 469 438 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 469 474 440 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G228A</sup>
###xml 808 812 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 987 991 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1122 1123 1090 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
TPalpha- and TPbeta-mediated RhoA Activation. HEK.TPalpha, HEK.TPbeta and HEK293 cells were serum-starved for 5 h before treatment (Panel A) for 10 min with vehicle or the indicated concentrations of U46619 or (Panel B) with 100 nM U46619 for the specified times, where cells treated with vehicle for 30 min acted as the control. Panel C: Alternatively, HEK.TPalpha and HEK.TPbeta cells were transiently transfected with plasmids encoding GalphaqQ209l,D277N or Galpha12G228A . Some 48 h post-transfection, cells were serum-starved for 5 h before treatment for 10 min with vehicle or 100 nM U46619. Active Rho was precipitated from the cell lysates using the Rho pulldown assay involving its binding to the GST-RBD (Rho binding domain of rhotekin)-fusion protein, separated by SDS-PAGE and immunoblotted with anti-RhoA antibody (Upper panels). Aliquots of cell lysates (typically 10 mul /lane corresponding to 1.25% of total cell lysate) were also analyzed for total RhoA expression with anti-RhoA antibody (Lower panels). The bar charts to the right of the panels signify mean fold increases in Rho activation +/- S.E.M. (n = 3-6) where basal levels are assigned a value of 1.0.
###end p 66
###begin p 67
###xml 617 628 582 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209l,D277N</sup>
###xml 638 640 599 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 640 645 601 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G228A</sup>
###xml 926 930 886 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 965 969 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1168 1169 1126 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
TPalpha and TPbeta-mediated F-Actin Polymerization and Cofilin Phosphorylation. Panel A: HEK.TPalpha, HEK.TPbeta and HEK293 cells were serum-starved for 5 h before treatment with the vehicle (MEM) or 10 nM U46619 for 10 min. Following fixation and permeabilization, F-actin polymerization was detected with Alexa Fluor(R) 488 phalloidin followed by fluorescence microscopy. Panel B: HEK.TPalpha, HEK.TPbeta and HEK293 cells were serum-starved for 5 h before treatment for 10 min with 0-10 muM U46619. Panel C: Alternatively, HEK.TPalpha and HEK.TPbeta cells were transiently transfected with plasmids encoding GalphaqQ209l,D277N or Galpha12G228A. Some 48 h post-transfection, cells were serum-starved for 5 h before treatment for 10 min with vehicle or 100 nM U46619. Aliquots of the cell lysates (typically 10 mul/lane corresponding to 1.25% of total cell lysate) in B and C were separated by SDS-PAGE and immunoblotted with anti-Phospho cofilin (Upper panels) or anti-cofilin (Lower panels) antibodies to detect phosphorylated and total cofilin expression. The bar charts to the right of the panels signify mean fold increases in cofilin phosphorylation +/- S.E.M. (n = 3-6) where basal levels were assigned a value of 1.0. (The reader is referred to the web version of this article to see color images of this figure, where relevant.)
###end p 67
###begin p 68
###xml 509 513 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 733 734 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 970 971 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 983 984 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Cicaprost- and SIN-1-induced desensitization of TP-mediated signaling. Panels A-C: HEK.TPalpha and HEK.TPbeta cells were serum starved for 5 h before treatment for 10 min with vehicle (Panels A and B), 0.01-10 muM Cicaprost (Panel A), 0.05-50 muM SIN-1 (Panel B), 1 muM BW345C or 10 muM FK409 (Panel C). Thereafter, cells were incubated with 100 nM U46619 for 10 min (Panels A-C). Active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (Upper panels). Cell lysates were analyzed by western blotting for total RhoA expression (Lower panels). The bar charts to the right of the panels signify mean fold increases in Rho activation +/- S.E.M. (n = 3-6) where basal levels were assigned a value of 1.0. The asterisks indicates that the level of U46619-mediated RhoA activation was significantly reduced in the presence of Cicaprost, Sin-1, BW245C and FK409 where ⁎ and ⁎⁎ indicates p < 0.05 and p < 0.01, respectively.
###end p 68
###begin p 69
###xml 844 848 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 883 887 865 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1005 1006 985 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1227 1228 1207 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Cicaprost- and SIN-1-induced desensitization of TP-mediated signaling. Panel A: HEK.TPalpha and HEK.TPbeta cells were serum starved for 5 h before treatment for 10 min with vehicle (Vehicle), 10 nM U46619 (U46619), 100 nM Cicaprost followed by 10 nM U46619 (U46619, Cicaprost) or 500 nM SIN-1 followed by 10 nM U46619 (U46619, SIN-1). F-actin formation was detected with Alexa Fluor(R) 488 phalloidin followed by fluorescence microscopy. Images presented are representative of the majority of cells examined and of 3/4 independent experiments. Panel B. HEK.TPalpha and HEK.TPbeta cells were serum starved for 5 h before treatment for 10 min with vehicle (-), 1 muM Cicaprost or 10 muM SIN-1 (Panel B). Thereafter, cells were incubated with vehicle (-) or 100 nM U46619 for 10 min. Cell lysates were separated by SDS-PAGE and immunoblotted with anti-Phospho cofilin (Upper panels) or anti-cofilin (Lower panels) antibodies. The bar charts signify mean fold increases in cofilin phosphorylation +/- S.E.M. (n = 3-6) where basal levels were assigned a value of 1.0. The asterisks indicates that the level of U46619-mediated cofilin phosphorylation was significantly reduced in the presence of Cicaprost or Sin-1 where ⁎ indicates p < 0.05. (The reader is referred to the web version of this article to see color images of this figure, where relevant.)
###end p 69
###begin p 70
###xml 99 104 95 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 117 122 109 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 138 147 126 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331,329A</sup>
###xml 518 522 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 662 667 642 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S329A</sup>
###xml 680 685 656 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331A</sup>
###xml 701 710 673 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S331,329A</sup>
Cicaprost- and SIN-1-induced desensitization of TP Signaling in HEK 293 cells. Panel A: HEK.TPalphaS329A, HEK.TPalphaS331A and HEK.TPalphaS331,329A cells were serum-starved for 5 h before treatment for 10 min with vehicle (-), 5 muM SIN-1, 10 muM FK409, 1 muM Cicaprost or 1 muM BW245C as indicated. Thereafter, cells were incubated for 10 min with vehicle (-) or 100 nM U46619 for 10 min. Active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (Upper panels). Cell lysates were analyzed by western blotting for total RhoA expression (Lower panels). Panel B: HEK.TPalphaS329A, HEK.TPalphaS331A and HEK.TPalphaS331,329A cells were serum starved for 5 h before treatment for 10 min with vehicle, 500 nM SIN-1 or 100 nM Cicaprost. Thereafter, cells were incubated for 10 min with vehicle (-) or 10 nM U46619 for 10 min. F-actin formation was detected with Alexa Fluor(R) 488 phalloidin followed by fluorescence microscopy. Images presented are representative of the majority of cells examined in 8 independent fields and of 3/4 independent experiments. (The reader is referred to the web version of this article to see color images of this figure, where relevant.)
###end p 70
###begin p 71
###xml 335 339 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 987 991 958 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1026 1030 997 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1247 1248 1216 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 38 43 <span type="species:ncbi:9606">human</span>
TP-mediated Rho signaling in 1degrees human Aortic Smooth Muscle Cells. Panel A: 1degrees AoSMCs were serum starved for 20 h before treatment for 10 min with vehicle (-) or 0.001-10 muM U46619 as indicated. Active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (Upper panels). Cell lysates were analyzed by western blotting for total RhoA expression (Lower panels). Panel B: 1degrees AoSMCs were serum starved for 5 h before treatment for 10 min with vehicle or 1 muM U46619 for 10 min. F-actin formation was detected with Alexa Fluor(R) 488 phalloidin followed by fluorescence microscopy. Images presented are representative of the majority of cells examined and of 3/4 independent experiments. Panel C: 1degrees AoSMCs were serum starved for 20 h before treatment for 10 min with vehicle (-) or 0.001-10 muM U46619 as indicated. Cell lysates were separated by SDS-PAGE and immunoblotted with anti-Phospho cofilin (Upper panels) or anti-cofilin (Lower panels) antibodies to detect phosphorylated and total cofilin expression. The bar charts to the right of the panels signify mean fold increases in Rho activation or cofilin phosphorylation +/- S.E.M. (n = 3-6) where levels of basal levels are assigned a value of 1.0. (The reader is referred to the web version of this article to see color images of this figure, where relevant.)
###end p 71
###begin p 72
###xml 464 468 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 780 781 761 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1036 1037 1017 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Desensitization of TP Signaling in 1degrees h.AoSMCs. 1degrees AoSMCs were serum starved for 20 h before treatment for 10 min with vehicle (-), 1 muM Cicaprost (Panel A), 5 muM SIN-1 (Panel B), 1 muM BW245C (Panel C) or 10 muM FK409 (Panel D). Thereafter, cells were incubated for 10 min with vehicle (-) or 1 muM U46619, as indicated. Active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (GST-RBD pulldown) while aliquots of cell lysates were analyzed by western blotting for total RhoA expression, phospho-cofilin and total cofilin expression as indicated. The bar charts to the right of the panels signify mean fold increases in Rho activation or cofilin phosphorylation +/- S.E.M. (n = 3-6) where basal levels are assigned a value of 1.0. The asterisks indicates that the level of U46619-mediated RhoA activation and cofilin phosphorylation was significantly reduced in the presence of Cicaprost, Sin-1, BW245C or FK409 where ⁎ indicates p < 0.05.
###end p 72
###begin p 73
###xml 205 212 187 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 231 237 206 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 324 330 292 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 378 385 340 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 500 508 451 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LaminA/C</sub>
###xml 610 614 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 725 729 669 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 829 836 766 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 843 849 776 779 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 858 866 788 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LaminA/C</sub>
###xml 1086 1090 1016 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1342 1343 1270 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1442 1449 1366 1369 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 1468 1474 1385 1388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 1641 1642 1555 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1651 1652 1565 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1664 1665 1578 1579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Effect of siRNA-mediated down-regulation of TPalpha and TPbeta Expression on Rho-signaling in HEK 293 cells. Panel A: HEK.TPalpha and HEK.TPbeta cells were transfected with siRNA-directed to TPalpha (siRNATPalpha) and TPbeta (siRNATPbeta), respectively, for 0-72 h. As controls, HEK.TPalpha cells were transfected with siRNATPbeta or HEK.TPbeta cells were transfected with siRNATPalpha for 72 h. Alternatively, as additional controls, HEK.TPalpha cells or HEK.TPbeta cells were transfected with siRNALaminA/C for 72 h (Right panels). HA-tagged TPalpha or TPbeta expression was detected by immunoblotting using anti-HA 3F10 antibody (Upper panels) or equal protein loading was verified by secondary screening of blots with an anti-HDJ2 antibody (Lower panels). Panel B: HEK.TPalpha and HEK.TPbeta cells were transfected with siRNATPalpha, siRNATPbeta or siRNALaminA/C for 72 h, as indicated. Thereafter, cells were incubated for 10 min with vehicle (-) or 100 nM U46619 for 10 min. Active Rho was precipitated from the cell lysates using GST-RBD fusion protein and immunoblotted with an anti-RhoA antibody (Upper panels). Cell lysates were analyzed by western blotting for total RhoA expression (Lower panels). The bar charts to the right of the panels signify mean fold changes in TP isoform expression (A) and Rho activation (B) +/- S.E.M. (n = 3-6) where basal levels are assigned a value of 1.0. The asterisks indicates that TPalpha (siRNATPalpha) and TPbeta (siRNATPbeta) expression (Panel A) or U46619-mediated RhoA activation (Panel B) was significantly reduced in the presence of their respective siRNAs where ⁎, ⁎⁎ and ⁎⁎⁎ indicates p < 0.05, p < 0.01 and p < 0.001 respectively.
###end p 73
###begin p 74
###xml 195 202 172 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 218 224 188 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 245 254 212 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lamin A/C</sub>
###xml 447 451 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 463 467 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 547 551 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1130 1134 1076 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1632 1636 1575 1579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1790 1794 1733 1737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1829 1833 1772 1776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anti</italic>
###xml 1993 1994 1934 1935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2215 2222 2152 2155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 2241 2247 2171 2174 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 2274 2275 2201 2202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2287 2288 2214 2215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2383 2384 2308 2309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2632 2639 2557 2560 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#945;</sub>
###xml 2648 2654 2569 2572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP&#946;</sub>
###xml 2680 2681 2598 2599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2693 2694 2611 2612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 542 546 <span type="species:ncbi:9925">goat</span>
###xml 552 558 <span type="species:ncbi:9986">rabbit</span>
Effect of siRNA-mediated down-regulation of TPalpha and TPbeta Expression on Rho-signaling in 1degrees h.AoSMCs. Panels A-D: 1degrees AoSMCs were transfected with siRNA-directed to TPalpha (siRNATPalpha), TPbeta (siRNATPbeta) or Lamin A/C (siRNALamin A/C) for 72 h where non-transfected cells served as controls, as indicated. In Panel A, following fixation and permeabilization, cells were screened by indirect immunoflourescence microscopy with anti-TPalpha or anti-TPbeta isoform specific 1degrees antibody and stained using FITC-labelled goat anti-rabbit IgG, where cell nuclei were counter stained with propidium iodide. In Panel A, data are representative of 3 independent experiments where a total of 16 independent fields of cells were analysed for each TP isoform. It was estimated that there was greater than 70% reduction TPalpha/TPbeta expression in 80% of cells analysed. In Panel B, cells were serum-starved for 20 h before treatment for 10 min with vehicle or 1 muM U46619 as indicated. Active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (Active RhoA) while cell lysates were analyzed for total RhoA expression, phospho-cofilin and total cofilin expression as indicated. Panels C and D, the cells were serum-starved for 20 h before treatment for 10 min with vehicle, 1.0 muM Cicaprost or 5.0 muM SIN-1. Thereafter, cells were incubated for 10 min with vehicle (-) or 1 muM U46619. In Panel C, active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (Upper panels) while cell lysates were analyzed for total RhoA expression (Lower panels). In Panel D, cell lysates were immunoblotted with anti-Phospho cofilin (Upper panels) or anti-cofilin (Lower panels) antibodies. In Panel B, the bar charts to the right signify mean fold changes in Rho activation and cofilin phosphorylation +/- S.E.M. (n = 3-6) where basal levels are assigned a value of 1.0. The asterisks indicates that U46619-mediated RhoA activation and cofilin phosphorylation was significantly reduced in the presence of their respective TPalpha (siRNATPalpha) and TPbeta (siRNATPbeta) siRNAs where ⁎ indicates p < 0.05 and p < 0.01, respectively. The bar charts below Panels C and D depict mean reductions (+/- S.E.M., n = 3-6) in U46619-mediated Rho activation (C) and cofilin phosphorylation (D) in response to pre-treatment with Sin-1 and Cicaprost, and the asterisks indicate that the level of desensitization was significantly altered in the presence of the siRNATPalpha or siRNATPbeta where ⁎ and ⁎⁎ indicates p < 0.05 and p < 0.01, respectively. (The reader is referred to the web version of this article to see color images of this figure, where relevant.)
###end p 74
###begin p 75
###xml 96 97 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 152 153 134 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 187 188 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 209 211 188 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 212 213 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 212 213 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 238 240 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 285 287 264 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 344 346 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 451 453 423 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 825 827 797 799 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 1004 1006 976 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1355 1357 1320 1322 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1423 1426 1384 1387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 1434 1437 1395 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">331</sup>
###xml 1554 1557 1511 1514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
###xml 1794 1797 1748 1751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sup>
Model of TPalpha and TPbeta-mediated RhoA activation and Signaling. Panels A and B: Agonist (TXA2/U46619)-activated TPalpha and TPbeta couples to Galphaq/PLCbeta, yielding increases in IP3, mobilization of [Ca2+]i leading to sequential Ca2+/calmodulin-dependent activation of MLCK, MLC20 phosphorylation and actomyosin formation resulting in Ca2+-dependent F actin polymerization. Agonist-activated TPalpha and TPbeta can simultaneously co-couple to G12/RhoGEF to activate RhoA and a host of its effectors including Rho kinase (ROCK), mammalian diaphanous protein (mDIA), Rhotekin, protein kinase (PK)N, amongst many others. ROCK phosphorylates: (i) the myosin-binding subunit (MBS) of myosin phosphatase (MPTase), inhibiting its activity; (ii) and activates CPI-17, a phosphorylation-dependent inhibitor of MPTase; (iii) MLC20 itself; (iv) LIM kinase (LIMK) which, in turn, phosphorylates and inactivates the actin depolymerizing agent Cofilin. These combined actions of ROCK contributes to the Rho A/Ca2+-independent mechanism for regulating stress fibre formation in non-muscle cells, smooth muscle contraction and platelet shape change. Panel A: The second messenger kinases cAMP-dependent PKA and cGMP-dependent PKG, activated in response to prostacyclin and NO signalling, respectively, cannot only impair TPalpha-mediated Gq-PLCbeta signaling and G12-RhoGEF signaling through direct phosphorylation of TPalpha at Ser329 and Ser331, respectively, but may also impair that TPalpha-mediated signalling, such as at the level of RhoA itself through Ser188 phosphorylation. Panel B: On the other hand, as TPbeta is not subject to direct PKA or PKG phosphorylation, its signaling by prostacyclin or NO may only be regulated at downstream intermediary level(s), such as at the level of RhoA (Ser188) phosphorylation. Y27632 is a selective inhibitor of Rho kinase. (The reader is referred to the web version of this article to see color images of this figure, where relevant.)
###end p 75

